<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005304.pub2" GROUP_ID="AIRWAYS" ID="128305012109111078" MERGED_FROM="" MODIFIED="2012-09-06 14:24:02 +0100" MODIFIED_BY="Emma Welsh" NOTES="&lt;p&gt;Hi Emma&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;I have edited the review. Your suggestions are in black. My response to what you suggested is after every paragraph here. Also I have edited et al from the reference you suggested. Another comment about the section differences between protocol and review. It should read &amp;quot;We had decided to include the study that examined children aged &amp;lt;15 years with tracheomalacia with associated respiratory symptoms&amp;quot; For some reason it had been edited to &amp;gt;15 years (which would make it an adult review). I have changed it back to &amp;lt;15 years. &lt;br&gt;&lt;br&gt;your review update on tracheomalacia has come back from copy editing. The copy editor made changes for consistency on the term nebulised recombinant human deoxyribonuclease (rhDNase). Please check that you are happy with this presentation which is now, hopefully, universal. We agree with addition of word nebulised everywhere rhDNase has been used.&lt;br&gt;&lt;br&gt;The copy editor noticed some inconsistencies around the term 'tracheomalacia', 'malacia', and 'airway malacia'. Could we pick one out and stick to it please? If malacia refers to something slightly different and is needed, this needs to be explained. I had mentioned it earlier that we have used the term airway malacia because the authors in the trial that we reviewed have called it airway malacia.The title of their paper is &amp;quot;Recombinant Human DNase in Children With Airway&lt;br&gt;Malacia and Lower Respiratory Tract Infection&amp;quot; We have explained that in included studies. We have also described the term malacia and airway malacia in PLS.&lt;br&gt;&lt;br&gt;The copy-editor also pointed out that there was no description of tracheomalacia at the start of the plain language summary (PLS). I have added this in for you - it's been edited from wikipedia, so do feel free to edit it yourself, but I think it's a good start. The PLS is a standalone document and therefore we have to make sure that its contains as much relevant information as possible and is completely consistent with the rest of the review - as well as being understandable by a lay audience. You will also see that I have added some more specific information about the benefits of the drug in the trial as we know that readers are interested in this. However, you talk about harms in the PLS; this was not included in the abstract and the two sections MUST be consistent - and with the review. Speaking to Chris, we toned down the harms in the abstract, so could you do the same in the PLS please? Furthermore I have deleted the sentence &amp;quot;nebulised rhDNase should not be used until future studies indicate otherwise&amp;quot; which is a recommendation which are not allowed in cochrane reviews and is not consistent with the abstract. Have added information about the drug and have edited the PLS.&lt;br&gt;&lt;br&gt;Regards&lt;/p&gt;&lt;p&gt;Vikas&lt;br&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;Vikas Goya 25/06/2012&lt;/p&gt;&lt;p&gt;Thanks for the suggestions Emma. I have made changes as suggested by you.&lt;/p&gt;&lt;p&gt;Regards&lt;/p&gt;&lt;p&gt;Vikas&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;Emma, 21/06/2012&lt;/p&gt;&lt;p&gt;Thanks Vikas for your response and amendments.&lt;/p&gt;&lt;p&gt;The review update is almost ready for peer review. Before that however, we'd like you to take another look at the SOF table.&lt;/p&gt;&lt;ul&gt;&lt;li&gt;Chris and I feel that the GRADE must be of 'low quality' because the review contains only one very small trial and this will need replication on a larger number of children in the future - we have made this change already.&lt;/li&gt;&lt;li&gt;SOF must contain an absolute maximum of 7 outcomes, so please delete some of the secondary outcomes. it's not recommended to have the same outcome twice - so I would condense a day and night scores by picking the most important one and perhaps making a note in the comments box about the other one if you feel it's important.&lt;/li&gt;&lt;li&gt;What is visual analog score? QoL? if so this need to be made clear in the SOF table and in the heading for the data and analyses&lt;/li&gt;&lt;li&gt;We have moved the confidence intervals to the correct place which is next to the treatment effect&lt;/li&gt;&lt;li&gt;please provide more information on scales in the table (see notes in table)&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;---------------------&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;Vikas Goyal's response&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;Thanks for your suggestions Emma. I have put a not in front of each suggestion to explain what I have done.&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;Emma J's notes 13/6/12&lt;/b&gt;&lt;/p&gt;&lt;p&gt;Anne - could you check if you still need the following refs which are not linked please? (Higgins 2003, Elbourne 2002, Jadad 1996 &amp;amp; Jokinen 1977). Thank you! Also, I moved Masters 2005 into 'Other published versions of this review'. Thanks and unlinked refs removed. &lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;Emma's notes 24/05/2012&lt;/p&gt;&lt;p&gt;Thanks very much for submitting this update! Good to have a trial in this review.&lt;/p&gt;&lt;ul&gt;&lt;li&gt;Abstarct&lt;/li&gt;&lt;ul&gt;&lt;li&gt;need to include number of children in the trial- done&lt;/li&gt;&lt;li&gt;include a sentence on the risk of bias in the study- done&lt;/li&gt;&lt;li&gt;comment on the quality of the data in line with summary of findings table done&lt;/li&gt;&lt;/ul&gt;&lt;li&gt;Background, why it is important to do this review - was that incidence figure from Australia? please elaborate the incidence is from a study in Netherlands ( Dr. Boogaard). Has been referenced .&lt;/li&gt;&lt;li&gt;stick to using 'tracheomalacia' rather than abbreviations throughout review Have tried to take care of that, although the paper we reviewed used the term airway malacia, instead of tracheomalacia so I have used their terminology as well. &lt;/li&gt;&lt;li&gt;included studies - must include comparisons (additionally, if it's not placebo, you need to amend the legend for the forest plot!!)didn't understand this question- In the intervention section of included studies, I have explained the study drug and placebo.&lt;/li&gt;&lt;li&gt;I learned today that sputum in people with CF is high in DNA. Could you expand on this to save the layperson googling it?- done &amp;amp; referenced&lt;/li&gt;&lt;li&gt;risk of bias - requires a comment for the blank cell- Done&lt;/li&gt;&lt;li&gt;delete two figures as the maximum allowed number is six - Edited figures&lt;/li&gt;&lt;li&gt;analyses&lt;/li&gt;&lt;ul&gt;&lt;li&gt;the comparison tree is set up incorrectly. You need to have one comparison tree for each comparison and all the outcomes listed below that. I have amended this for you - check that you are happy and then delete your other 'comparisons' - you will have to recreate and link your figures. Done - although I think the previous way of dividing comparisons into 4 tables was more reader friendly&lt;/li&gt;&lt;li&gt;need to turn off all the totals in the forest plot as you cant 'pool' a single study- done &lt;/li&gt;&lt;/ul&gt;&lt;li&gt;Conclusions - be more specific about the required outcomes for future trials&lt;/li&gt;&lt;li&gt;&lt;span&gt;characteristics of included studies tables - &lt;/span&gt;73% is&lt;span&gt; copied verbatim from the trial. Could you summarise the information e.g. using bullet points and headings?&lt;/span&gt;- done&lt;/li&gt;&lt;li&gt;summary of findings table. I have provided the bones of a SOF table. Please read chapter 12 of the Cochrane Handbook and then edit the table as you see fit.- done- also see below&lt;/li&gt;&lt;li&gt;Conclusions should not tell readers what to do, and &amp;quot;likely harmful&amp;quot; is too strong. No significant differences are seen but the CI is too wide to exclude either harm or benefit. I do not agree that likely harmful is to strong, as this was shown in at least one outcome. It was a well conducted, RCT which I think had a low risk of bias over all (even though it was sponsored by a pharmaceutical company), so the use of term likely harmful is appropriate esp in light of clinicians using it in many clinical practices. We have commented on is on the basis of a good quality trial. Also the trial has a low risk of bias and no publication bias or indirectness has been detected so we disagree that the data should be graded down to very low . &lt;/li&gt;&lt;/ul&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;----------------------------------------&lt;/p&gt;&lt;p&gt;Exported from Review Manager 4.2.7&lt;br&gt;Editing by CJC Aug 4 05&lt;/p&gt;&lt;p&gt;Authors' Contribution: fine&lt;/p&gt;&lt;p&gt;Objectives: fine&lt;/p&gt;&lt;p&gt;References: fine&lt;/p&gt;&lt;p&gt;Table of included studies: none&lt;/p&gt;&lt;p&gt;Metaview Labels: none&lt;/p&gt;&lt;p&gt;Synopsis: first sentence added.&lt;/p&gt;&lt;p&gt;Abstract: fine&lt;/p&gt;&lt;p&gt;Methods: fine&lt;/p&gt;&lt;p&gt;Results: fine&lt;/p&gt;&lt;p&gt;Discussion : good&lt;/p&gt;&lt;p&gt;Contentious issues&lt;/p&gt;&lt;p&gt;Spellchecked: Done&lt;/p&gt;&lt;p&gt;Next action: Back to Toby for submission&lt;/p&gt;&lt;p&gt;&lt;br&gt;=============================&lt;br&gt;cjc 17 feb 2005&lt;br&gt;PROTOCOL&lt;/p&gt;&lt;p&gt;Reviewers Contributions: fine&lt;/p&gt;&lt;p&gt;References: fine&lt;/p&gt;&lt;p&gt;Objectives: fine&lt;/p&gt;&lt;p&gt;Methods: fine but Elbourne has been missed from the references and Higgins added for the I-square statistic. I have added these and created links. I have also added a reference to Visual Rx.&lt;/p&gt;&lt;p&gt;Contentious issues: - [Square brackets] are traditionally reserved for included study references so I have changed these to (round brackets)&lt;/p&gt;&lt;p&gt;Next action: to Toby for submission with a copy to Anne.&lt;/p&gt;&lt;p&gt;&lt;br&gt;===============================================&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;search strategy checked 8/2/05 Liz&lt;/p&gt;&lt;p&gt;Old title: #Interventions for primary (intrinsic) tracheomalacia in children&lt;br&gt;Old title: #Interventions for primary (intrinsic) tracheomalacia in children (WITH CHRIS 290705)&lt;/p&gt;" NOTES_MODIFIED="2012-09-06 14:22:12 +0100" NOTES_MODIFIED_BY="Emma Welsh" REVIEW_NO="TRAC-OTH" REVMAN_SUB_VERSION="5.1.7" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2012-09-06 14:24:02 +0100" MODIFIED_BY="Emma Welsh">
<TITLE>Interventions for primary (intrinsic) tracheomalacia in children</TITLE>
<CONTACT MODIFIED="2012-09-06 14:24:02 +0100" MODIFIED_BY="Emma Welsh"><PERSON ID="64129408761224059620120312114924" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Vikas</FIRST_NAME><LAST_NAME>Goyal</LAST_NAME><EMAIL_1>drvikasgoyal@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Queensland Children's Medical Research Institute</DEPARTMENT><ORGANISATION>The University of Queensland</ORGANISATION><CITY>Brisbane</CITY><COUNTRY CODE="AU">Australia</COUNTRY></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2012-09-06 14:24:02 +0100" MODIFIED_BY="Emma Welsh"><PERSON ID="64129408761224059620120312114924" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Vikas</FIRST_NAME><LAST_NAME>Goyal</LAST_NAME><EMAIL_1>drvikasgoyal@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Queensland Children's Medical Research Institute</DEPARTMENT><ORGANISATION>The University of Queensland</ORGANISATION><CITY>Brisbane</CITY><COUNTRY CODE="AU">Australia</COUNTRY></ADDRESS></PERSON><PERSON ID="2EADF36782E26AA20129AA21DA502854" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>I</FIRST_NAME><MIDDLE_INITIALS>Brent</MIDDLE_INITIALS><LAST_NAME>Masters</LAST_NAME><POSITION>Consultant in Respiratory and Sleep Medicine</POSITION><EMAIL_1>brent_masters@health.qld.gov.au</EMAIL_1><ADDRESS><DEPARTMENT>Queensland Children's Medical Research Institute</DEPARTMENT><ORGANISATION>The University of Queensland</ORGANISATION><ADDRESS_1>Herston Rd</ADDRESS_1><ADDRESS_2>Herston</ADDRESS_2><CITY>Brisbane</CITY><ZIP>4029</ZIP><REGION>Queensland</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>61 7 36369047</PHONE_1><PHONE_2>61 402046051</PHONE_2><FAX_1>61 7 3631958</FAX_1></ADDRESS></PERSON><PERSON ID="12396" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Anne</FIRST_NAME><MIDDLE_INITIALS>B</MIDDLE_INITIALS><LAST_NAME>Chang</LAST_NAME><POSITION>Senior Research Principal Fellow, NHMRC Pracitioner Fellow</POSITION><EMAIL_1>Anne.Chang@menzies.edu.au</EMAIL_1><EMAIL_2>Anne.chang@menzies.edu.au</EMAIL_2><ADDRESS><DEPARTMENT>Menzies School of Health Research</DEPARTMENT><ORGANISATION>Charles Darwin University</ORGANISATION><ADDRESS_1>PO Box 41096</ADDRESS_1><CITY>Casuarina</CITY><ZIP>0811</ZIP><REGION>Northern Territories</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 7 36369149</PHONE_1><FAX_1>+61 7 36361958</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2012-09-06 14:22:12 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="8" MONTH="3" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="8" MONTH="3" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="2" YEAR="2014"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2005"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2005"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2005"/>
</DATES>
<WHATS_NEW MODIFIED="2012-09-05 13:49:24 +0100" MODIFIED_BY="Toby J Lasserson">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2012-09-05 13:49:24 +0100" MODIFIED_BY="Toby J Lasserson">
<DATE DAY="8" MONTH="3" YEAR="2012"/>
<DESCRIPTION>
<P>One randomised controlled trial (RCT) identified and added to the review. We added a summary of findings table and updated the text including the plain language summary and background.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-05-24 16:30:06 +0100" MODIFIED_BY="Emma J Welsh">
<DATE DAY="8" MONTH="3" YEAR="2012"/>
<DESCRIPTION>
<P>New literature search run</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-04-07 11:45:54 +0100" MODIFIED_BY="Toby J Lasserson">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-04-07 11:45:54 +0100" MODIFIED_BY="Toby J Lasserson">
<DATE DAY="7" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="25" MONTH="7" YEAR="2005"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2012-08-15 13:31:59 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2012-08-15 13:31:59 +0100" MODIFIED_BY="Anne Chang">
<SOURCE MODIFIED="2012-08-15 13:31:59 +0100" MODIFIED_BY="Anne Chang">
<NAME>Royal CHildren's Hospital Foundation</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION>
<P>Program grant awarded by the Queensland Children's Medical Research Institute </P>
</DESCRIPTION>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2012-08-15 13:30:29 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2012-05-21 12:07:36 +0100" MODIFIED_BY="[Empty name]">
<NAME>National Health and Medical Research Council</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION>
<P>Fellowship to AC (grant number 545216)</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2012-08-15 13:30:29 +0100" MODIFIED_BY="Anne Chang">
<NAME>Centre of Research Excellence in Lung Health of Aboriginal and Torres Strait Islander Children</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION>
<P>NHMRC grant number 1040830</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2012-09-06 14:18:42 +0100" MODIFIED_BY="Emma Jackson">
<SUMMARY MODIFIED="2012-09-06 14:18:42 +0100" MODIFIED_BY="Toby J Lasserson">
<TITLE MODIFIED="2012-08-29 02:46:53 +0100" MODIFIED_BY="Emma J Welsh">Interventions for primary (intrinsic) tracheomalacia in children</TITLE>
<SUMMARY_BODY MODIFIED="2012-09-06 14:18:42 +0100" MODIFIED_BY="Toby J Lasserson">
<P>The term malacia is derived from the Greek word 'malakia', meaning soft. In tracheomalacia, the walls of trachea (or windpipe) are softer than normal, which can lead to partial collapse (falling in) of the windpipe. This collapse usually happens when more air is needed, such as during exercise. The word 'primary' refers to tracheomalacia in which the windpipe itself is the cause of the disease, where as secondary tracheomalacia is compressed due to some other abnormality near to the windpipe. The most common symptom of tracheomalacia is expiratory stridor (high-pitched wheezing sound). If the symptoms are severe enough, treatment such as mechanical ventilation, tracheal stenting (mesh tube inserted into windpipe to hold it open) or surgery may be needed.</P>
<P>We wanted to find out which out of these possible treatments was most effective. We found only one randomised controlled trial (RCT) that assessed nebulised recombinant human deoxyribonuclease (rhDNase) which helps in breaking down the mucous and has been shown to be useful in aiding airway clearance in cystic fibrosis compared to placebo (no active treatment) in children with both tracheomalacia and a concurrent respiratory infection. This trial showed no evidence of benefit in terms of the number of children who were cough-free two weeks after treatment. Also, there was less coughing reported, both during the day and at night, in the group who did not receive the intervention - however these differences were not statistically significant.</P>
<P>With the lack of evidence, the routine use of any therapies for intrinsic tracheomalacia cannot be recommended given the cost of nebulised rhDNase and the likely harmful effect. The decision to subject a child to any surgical or medical based therapies will have to be made on an individual basis, with careful consideration of the risk-benefit ratio for each individual situation.</P>
<P>It is unlikely that any RCT on surgically based management will ever be available for children with severe life-threatening illness associated with tracheomalacia. For those with less severe disease, RCTs on interventions such as antibiotics and chest physiotherapy are needed.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2012-09-05 14:08:34 +0100" MODIFIED_BY="Toby J Lasserson">
<ABS_BACKGROUND MODIFIED="2012-08-28 14:22:52 +0100" MODIFIED_BY="Emma J Welsh">
<P>Tracheomalacia, a disorder of the large airways where the trachea is deformed or malformed during respiration, is commonly seen in tertiary paediatric practice. It is associated with a wide spectrum of respiratory symptoms from life-threatening recurrent apnoea to common respiratory symptoms such as chronic cough and wheeze. Current practice following diagnosis of tracheomalacia includes medical approaches aimed at reducing associated symptoms of tracheomalacia, ventilation modalities of continuous positive airway pressure (CPAP) and bi-level positive airway pressure (BiPAP), and surgical approaches aimed at improving the calibre of the airway (airway stenting, aortopexy, tracheopexy).</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To evaluate the efficacy of medical and surgical therapies for children with intrinsic (primary) tracheomalacia.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2012-08-28 14:12:41 +0100" MODIFIED_BY="Toby J Lasserson">
<P>The Cochrane Airways Group searched the Cochrane Central Register of Controlled Trials (CENTRAL), the Cochrane Airways Group's Specialised Register, MEDLINE and EMBASE databases. The Cochrane Airways Group performed the latest searches in March 2012.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2012-08-28 13:09:30 +0100" MODIFIED_BY="Emma J Welsh">
<P>All randomised controlled trials (RCTs) of therapies related to symptoms associated with primary or intrinsic tracheomalacia.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2012-06-12 15:15:48 +0100" MODIFIED_BY="[Empty name]">
<P>Two reviewers extracted data from the included study independently and resolved disagreements by consensus.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2012-09-05 14:08:34 +0100" MODIFIED_BY="[Empty name]">
<P>We included one RCT that compared nebulised recombinant human deoxyribonuclease (rhDNase) with placebo in 40 children with airway malacia and a respiratory tract infection. We assessed it to be a RCT with overall low risk of bias. Data analysed in this review showed that there was no significant difference between groups for the primary outcome of proportion cough-free at two weeks (odds ratio (OR) 1.38; 95% confidence interval (CI) 0.37 to 5.14). However, the mean change in night time cough diary scores significantly favoured the placebo group (mean difference (MD) 1.00; 95% CI 0.17 to 1.83, P = 0.02). The mean change in daytime cough diary scores from baseline was also better in the placebo group compared to those on nebulised rhDNase, but the difference between groups was not statistically significant (MD 0.70; 95% CI -0.19 to 1.59). Other outcomes (dyspnoea, and difficulty in expectorating sputum scores, and lung function tests at two weeks also favoured placebo over nebulised rhDNase but did not reach levels of significance.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2012-09-05 14:08:34 +0100" MODIFIED_BY="[Empty name]">
<P>There is currently an absence of evidence to support any of the therapies currently utilised for management of intrinsic tracheomalacia. It remains inconclusive whether the use of nebulised rhDNase in children with airway malacia and a respiratory tract infection worsens recovery. It is unlikely that any RCT on surgically based management will ever be available for children with severe life-threatening illness associated with tracheomalacia. For those with less severe disease, RCTs on interventions such as antibiotics and chest physiotherapy are clearly needed. Outcomes of these RCTs should include measurements of the trachea and physiological outcomes in addition to clinical outcomes.<BR/>
</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2012-09-05 14:08:35 +0100" MODIFIED_BY="Emma Jackson">
<BACKGROUND MODIFIED="2012-08-28 13:11:50 +0100" MODIFIED_BY="Emma Jackson">
<P>Tracheomalacia is a disorder of the large airways where the trachea is deformed or malformed during respiration (<LINK REF="REF-Masters-2002" TYPE="REFERENCE">Masters 2002</LINK>). Tracheomalacia is commonly seen in tertiary paediatric practice (<LINK REF="REF-Masters-2002" TYPE="REFERENCE">Masters 2002</LINK>) and many of the children are only referred for assessment after repeated failure of therapies, which include asthma drug therapies (<LINK REF="REF-Gormley-1999" TYPE="REFERENCE">Gormley 1999</LINK>; <LINK REF="REF-Thomson-2002" TYPE="REFERENCE">Thomson 2002</LINK>). This large airway disorder can be classified as primary (intrinsic abnormality of the airway) or secondary (related to compression of trachea by another structure such as a mass). Primary tracheomalacia may occur in isolation, or in association with other malacia disorders (laryngomalacia and bronchomalacia), as part of a syndrome (e.g. Downs syndrome, Ehlers-Danlos syndrome), or with other congenital non-syndromic disorders (e.g. cardiac abnormalities, tracheoesophageal fistula etc.) (<LINK REF="REF-Austin-2003" TYPE="REFERENCE">Austin 2003</LINK>; <LINK REF="REF-Masters-2002" TYPE="REFERENCE">Masters 2002</LINK>). Some have classified tracheomalacia associated with other abnormalities as secondary tracheomalacia assuming that it is related to the compression effects. Embryologically, these tracheomalacia are related to a developmental abnormality with the associated condition (as opposed to because of the associated condition) (<LINK REF="REF-Beasley-1998" TYPE="REFERENCE">Beasley 1998</LINK>) and in general do not totally resolve after correction of the associated problem (such as in tracheoesophageal fistula (<LINK REF="REF-Kovesi-2004" TYPE="REFERENCE">Kovesi 2004</LINK>) or after thoracic vascular surgery (<LINK REF="REF-Horvath-1992" TYPE="REFERENCE">Horvath 1992</LINK>; <LINK REF="REF-van-Son-1993" TYPE="REFERENCE">van Son 1993</LINK>). Therefore we have classified these types of tracheomalacia as primary tracheomalacia with associated abnormalities. True secondary tracheomalacia generally resolves on removal of the offending agent (such as a mediastinal mass or lymph node) and thus will not be discussed in this review.</P>
<CONDITION MODIFIED="2012-08-28 13:11:27 +0100" MODIFIED_BY="[Empty name]">
<P>Tracheomalacia is associated with common respiratory symptoms (<LINK REF="REF-Masters-2009" TYPE="REFERENCE">Masters 2009</LINK>). The most common symptoms at presentation are persistent respiratory symptoms, in particular chronic cough and wheeze. These symptoms cover most of the common respiratory symptoms seen in children and thus it not surprising that diagnosis is often delayed (<LINK REF="REF-Gormley-1999" TYPE="REFERENCE">Gormley 1999</LINK>; <LINK REF="REF-Masters-2002" TYPE="REFERENCE">Masters 2002</LINK>; <LINK REF="REF-Wood-1997" TYPE="REFERENCE">Wood 1997</LINK>). <LINK REF="REF-Gormley-1999" TYPE="REFERENCE">Gormley 1999</LINK> described that 75% of children with congenital tracheomalacia secondary to congenital vascular anomaly had persistent cough at presentation. As these symptoms overlap with other respiratory disorders, it is also not surprising that the diagnosis and management of tracheomalacia is often suboptimal (<LINK REF="REF-Gormley-1999" TYPE="REFERENCE">Gormley 1999</LINK>). Other respiratory symptoms include recurrent infections and pneumonia, recurrent cyanosis, stridor, exertional dyspnoea and effort intolerance. Severe tracheomalacia may also be associated with difficult anaesthesia (<LINK REF="REF-Austin-2003" TYPE="REFERENCE">Austin 2003</LINK>) and increased CO<SUB>2</SUB> value during flexible bronchoscopy under general anaesthesia is associated with these airway lesions (<LINK REF="REF-Chang-2004" TYPE="REFERENCE">Chang 2004</LINK>). Non-respiratory symptoms related to tracheomalacia have also been described and these include dysphagia (<LINK REF="REF-Agrawal-1999" TYPE="REFERENCE">Agrawal 1999</LINK>) and gastroesophageal reflux (<LINK REF="REF-Bibi-2001" TYPE="REFERENCE">Bibi 2001</LINK>).</P>
<P>Tracheomalacia may be diagnosed by flexible and rigid bronchoscopy, radiological airway screening, chest computed tomography (CT) scan, magnetic resonance imaging (MRI) or tracheobronchogram. The current gold standard of diagnosing tracheomalacia is by visual assessment during bronchoscopy (<LINK REF="REF-Wright-2003" TYPE="REFERENCE">Wright 2003</LINK>) and flexible bronchoscopy is superior to rigid bronchoscopy for evaluation of tracheobronchomalacia (<LINK REF="REF-Midulla-2003" TYPE="REFERENCE">Midulla 2003</LINK>). Airway screening is a rather insensitive tool for diagnosis of tracheomalacia in children (<LINK REF="REF-Sanchez-2012" TYPE="REFERENCE">Sanchez 2012</LINK>). Flexible bronchoscopy provides the best assessment for the dynamic airway changes found in tracheobronchomalacia (<LINK REF="REF-Midulla-2003" TYPE="REFERENCE">Midulla 2003</LINK>). The other methods of diagnosis are less reliable and/or have major pitfalls. During flexible bronchoscopy, different visual descriptions of tracheomalacia have been described (<LINK REF="REF-Masters-2002" TYPE="REFERENCE">Masters 2002</LINK>). However the associated symptoms are similar (<LINK REF="REF-Masters-2002" TYPE="REFERENCE">Masters 2002</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2012-08-28 13:11:48 +0100" MODIFIED_BY="[Empty name]">
<P>The respiratory symptoms attributed to tracheomalacia are most likely primarily to be related to the effect of a narrowed airway generating altered airflow. Wheeze is generated from altered flow through a narrowed tube. Misdiagnosis of asthma in children with airway malacia disorders has been well described (<LINK REF="REF-Finder-1997" TYPE="REFERENCE">Finder 1997</LINK>). Cough is likely related to reduction of mucociliary clearance as the compressed airway impedes clearance of secretions (<LINK REF="REF-Finder-1997" TYPE="REFERENCE">Finder 1997</LINK>) which sets up a bronchitic process distal to the lesion. Exactly why this occurs is unknown but the possibility of a more subtle process that involves functional abnormalities in the development of the neurovascular and airway immunological, smooth muscle and epithelial cell lines would be biologically possible, but have not been described. Thus, it is also plausible that a change in anatomical improvement (if possible) may not necessary result in symptomatic improvement.</P>
<P>Thus, interventions for tracheomalacia include: procedures or medications that improve airway calibre (such as stents, aortopexy and continuous positive airway pressure), enhance airway clearance (such as mucoactive agents like hypertonic saline and nebulised recombinant human deoxyribonuclease (rhDNase)), short- and/or long-term antibiotics to treat and/or prevent infective exacerbations and reduce airway inflammation (such as corticosteroids).</P>
</INTERVENTION>
<THEORY MODIFIED="2012-08-28 13:11:49 +0100" MODIFIED_BY="[Empty name]">
<P>Current practice following diagnosis of tracheomalacia includes medical approaches aimed at reducing associated symptoms of tracheomalacia and surgical approaches aimed at improving the calibre of the airway (airway stenting, aortopexy) and thus reducing associated symptoms.</P>
</THEORY>
<IMPORTANCE MODIFIED="2012-08-28 13:11:50 +0100" MODIFIED_BY="[Empty name]">
<P>Children with tracheomalacia often have respiratory symptoms, and it is not an uncommon disease among children (incidence of approximately 1 in 1500 to 2500 children in a study in The Netherlands) (<LINK REF="REF-Boogaard-2005" TYPE="REFERENCE">Boogaard 2005</LINK>). The interventions described above may have serious and significant adverse events. Hence, there is a need for systematic evaluation of the effects of interventions aimed at reducing the respiratory symptoms related to tracheomalacia.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES>
<P>To evaluate the efficacy of medical and surgical therapies for children with intrinsic (primary) tracheomalacia.</P>
</OBJECTIVES>
<METHODS MODIFIED="2012-08-28 14:25:49 +0100" MODIFIED_BY="Emma Jackson">
<SELECTION_CRITERIA MODIFIED="2012-08-28 13:12:13 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2012-08-28 13:11:50 +0100" MODIFIED_BY="[Empty name]">
<P>All randomised controlled trials (RCTs) of therapies related to symptoms associated with primary or intrinsic tracheomalacia.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Children aged &lt; 15 years with tracheomalacia with associated respiratory symptoms. <BR/>Exclusion criteria: secondary tracheomalacia. </P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2012-08-28 13:11:54 +0100" MODIFIED_BY="[Empty name]">
<P>All randomised controlled comparisons of therapies for symptoms associated with primary or intrinsic tracheomalacia. We included trials that included the use of other medications or interventions if all participants had equal access to such medications or interventions.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2012-08-28 13:12:13 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2012-08-28 13:11:55 +0100" MODIFIED_BY="Emma J Welsh">
<OL>
<LI>Proportion of participants who were not cured or not substantially improved at follow-up (clinical failure).</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2012-08-28 13:12:13 +0100" MODIFIED_BY="Emma J Welsh">
<OL>
<LI>Proportion of participants who were not cured at follow-up.</LI>
<LI>Proportion of participants who not substantially improved at follow-up.</LI>
<LI>Mean difference (MD) in number of respiratory episodes (defined by diary cards or acute respiratory illness score).</LI>
<LI>Proportion requiring hospitalisation for respiratory illness.</LI>
<LI>MD in symptoms and signs (mean improvement in clinical state).</LI>
<LI>Proportion developing new respiratory complications such as bronchiectasis, bronchiolitis obliterans, etc.</LI>
<LI>Proportion requiring acute or complicated airway intervention (prolonged intubation, tracheostomy, etc.).</LI>
<LI>Proportion experiencing adverse effects of the intervention (e.g. death from surgery, surgical complications, etc.).</LI>
</OL>
<P>The proportion of participants who failed to improve on treatment and the mean clinical improvement were to be determined using the following hierarchy of assessment measures (i.e. where two or more assessment measures are reported in the same study, the outcome measure that is listed first in the hierarchy would be used).</P>
<OL>
<LI>Objective measurements of cough indices (cough frequency).</LI>
<LI>Symptomatic (Quality of life scale, Likert scale, visual analogue scale (VAS), level of interference of respiratory symptoms such as cough, wheeze, cyanotic events, etc. using diaries) - assessed by child.</LI>
<LI>Symptomatic (Quality of life scale, Likert scale, VAS, level of interference of respiratory symptoms such as cough, wheeze, cyanotic events, etc. using diaries) - assessed by the parents/carers.</LI>
<LI>Symptomatic (Likert scale, VAS, level of interference of respiratory symptoms such as cough, wheeze, cyanotic events, etc. using diaries) - assessed by clinicians.</LI>
<LI>Pulmonary function tests.</LI>
<LI>Bronchoscopic assessment of tracheomalacia (using flexible bronchoscopy).</LI>
<LI>Relevant airway markers consistent with neutrophillic inflammation.</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2012-08-28 13:12:21 +0100" MODIFIED_BY="[Empty name]">
<P>
<BR/>
<BR/>
</P>
<ELECTRONIC_SEARCHES MODIFIED="2012-08-28 13:12:21 +0100" MODIFIED_BY="[Empty name]">
<P>We used the following topic search strategy to identify the relevant randomised controlled trials (RCTs) listed in the electronic databases.<BR/>(" tracheomalacia " OR " tracheo-malacia " OR "malacia" OR " trachea abnormalities" OR "tracheal diseases" all as (text word) or (MeSH)) AND ("child" OR "children" OR "infant" as (text word) or (MeSH)). The full search strategies are shown in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>; <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>; and <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>. We identified trials from the following sources.</P>
<OL>
<LI>The Cochrane Controlled Trials Register (CENTRAL), which includes the Cochrane Airways Review Group's Specialised Trials Register, Issue 2 of 12, 2012.</LI>
<LI>MEDLINE 1946 to March 2012.</LI>
<LI>EMBASE 1980 to March 2012.</LI>
</OL>
<P>We did not impose any restriction on language of publication, or publication status. We conducted the searches in March 2012.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2012-06-12 15:27:45 +0100" MODIFIED_BY="[Empty name]">
<P>In addition, we searched the list of references in relevant publications and wrote to authors of trials included in the review.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2012-08-28 14:25:49 +0100" MODIFIED_BY="Emma Jackson">
<STUDY_SELECTION MODIFIED="2012-08-28 13:12:34 +0100" MODIFIED_BY="[Empty name]">
<P>From the title, abstract or descriptions, two authors independently reviewed literature searches to identify potentially relevant trials for full review. We searched bibliographies and texts to identify additional studies (IBM and AC in the original review and VG and AC in this updated review. From the full-text using specific criteria, VG and AC independently selected trials for inclusion. Disagreement would have been resolved by consensus, but there was no disagreement between the two authors.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2012-08-28 14:23:04 +0100" MODIFIED_BY="[Empty name]">
<P>We reviewed the trials that satisfied the inclusion criteria and recorded the following information: study setting; year of study; source of funding; patient recruitment details (including number of eligible children); inclusion and exclusion criteria; randomisation and allocation concealment method; numbers of participants randomised; blinding (masking) of participants; care providers and outcome assessors; intervention (duration and type); control; co-morbidities (all medical problems with particular attention to genetic syndromes and co-morbidities); existing respiratory problems; cointerventions; numbers of patients not followed up; reasons for withdrawals from study protocol (clinical, side effects, refusal and other), details on side effects of therapy; and whether intention-to-treat analyses were possible. We had planned to extract data on the outcomes described previously.</P>
<P>We extracted information from the study for the following characteristics.</P>
<OL>
<LI>Type of study (description of randomisation, blinding, allocation, withdrawals).</LI>
<LI>Participants (N, age range).</LI>
<LI>Intervention (type of intervention: medical or surgical, duration of intervention, cointerventions).</LI>
<LI>Outcomes (primary and secondary outcomes, timing of outcome assessments, adverse outcomes).</LI>
</OL>
<P>We planned to request further information from the trial authors where required. Dr Boogaard (<LINK REF="STD-Boogaard-2009" TYPE="STUDY">Boogaard 2009</LINK>) kindly provided us with his raw data that enabled us to calculate the number of participants who failed to improve at the end of two weeks.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2012-08-28 13:12:41 +0100" MODIFIED_BY="Emma Jackson">
<P>We assessed risk of bias in the trials for the following seven domains using the 'Risk of bias' table in Review Manager 5 (<LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>). The authors judged whether there was high or low risk of these biases. Where the risk was not clear, we stated as such.</P>
<OL>
<LI>Sequence generation.</LI>
<LI>Allocation concealment.</LI>
<LI>Blinding of participants and personnel.</LI>
<LI>Blinding of outcome assessment.</LI>
<LI>Incomplete outcome data.</LI>
<LI>Selective reporting.</LI>
<LI>Other potential sources of biases.</LI>
</OL>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2012-05-14 12:05:01 +0100" MODIFIED_BY="[Empty name]">
<P>We extracted data for each of the outcomes (where data were available) from the trial publication that fulfilled the inclusion criteria.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2012-05-14 12:05:02 +0100" MODIFIED_BY="[Empty name]">
<P>We sought to obtain data that were reported with patients (rather than events) as the unit of analysis for the primary outcomes.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2012-08-28 14:23:06 +0100" MODIFIED_BY="[Empty name]">
<P>We contacted the authors for missing data. For intention-to-treat analysis, we assumed that missing values would have had poor outcomes. We planned to perform sensitivity analyses to assess how sensitive the results are to the reasonable assumptions made in regards to the missing data.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2012-08-28 13:12:54 +0100" MODIFIED_BY="[Empty name]">
<P>We had planned to describe and explore heterogeneity between the study results and to use the 95% CI, estimated using a random-effects model, whenever there were concerns about statistical heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2012-08-28 13:12:54 +0100" MODIFIED_BY="[Empty name]">
<P>We had planned to identify and report on any selective reporting in the included trials. We would have tested publication bias using a funnel plot, if five or more studies were available in the review.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2012-08-28 14:25:49 +0100" MODIFIED_BY="[Empty name]">
<P>We had planned to combine data using Review Manager 5 (<LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>), with a view to using a fixed-effect mean difference (MD) (calculated as a weighted MD) for continuous data variables. If different scales were combined, we had intended to use the standardised mean difference (SMD).</P>
<P>For dichotomous outcome variables of each individual study, we calculated the odds ratios (ORs) using a modified intention-to-treat analysis (i.e. failure assumed if participant drops out of study). This analysis assumes that children not available for outcome assessment have not improved (and probably represents a conservative estimate of effect).</P>
<P>We intended to calculate a number needed to treat (benefit or harm) when possible for the different levels of risk as represented by control group event rates over a specified time period using the pooled OR and its CI using an online calculator, Visual Rx (<LINK REF="REF-Cates-2003" TYPE="REFERENCE">Cates 2003</LINK>). We constructed a 'Summary of findings' table according to recommendations in the Cochrane handbook of Systematic Reviews of Interventions (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2012-08-28 13:13:02 +0100" MODIFIED_BY="[Empty name]">
<P>We had planned an a priori subgroup analysis for:</P>
<OL>
<LI>age: infants (less than12 months) or children (aged 1 to 14 years);</LI>
<LI>presence of congenital (cardiac, tracheoesophageal fistula) syndromes;</LI>
<LI>medical therapies; and</LI>
<LI>surgical therapies.</LI>
</OL>
<P>As there was only a single study, a subgroup analysis was not applicable.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2012-08-28 13:13:02 +0100" MODIFIED_BY="[Empty name]">
<P>We had planned sensitivity analyses to assess the impact of the following potentially important factors on the overall outcomes.</P>
<OL>
<LI>Variation in the inclusion criteria.</LI>
<LI>Differences in other medications/procedures used in the intervention and comparison groups.</LI>
<LI>Analysis using a random-effects model.</LI>
<LI>Analysis by 'treatment received' or 'intention-to-treat'.</LI>
</OL>
<P>As there was only a single study, a sensitivity analysis was not applicable.<BR/>
</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2012-09-05 14:08:35 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2012-09-05 14:08:35 +0100" MODIFIED_BY="Toby J Lasserson">
<SEARCH_RESULTS MODIFIED="2012-08-28 13:13:09 +0100" MODIFIED_BY="[Empty name]">
<P>The original search in 2008 did not identify any eligible studies. The Airways Group search in March 2012 identified 118 potentially relevant titles since the last update of the review (2008). After assessing the abstracts, we retrieved five papers, out of which we considered only one study for inclusion in the review as it fulfilled the study eligibility criteria.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2012-09-05 14:08:35 +0100" MODIFIED_BY="[Empty name]">
<P>The single eligible study (<LINK REF="STD-Boogaard-2009" TYPE="STUDY">Boogaard 2009</LINK>) was conducted in children that had planned to include children aged 2 to 18 years. We included this study as children were aged 2.8 to 15.5 years. This RCT compared nebulised recombinant human deoxyribonuclease (rhDNase) with placebo in children with airway malacia and lower respiratory tract infection (LRTI). The episode of LRTI was defined by the authors as (an increase in) productive cough or dyspnoea, and/or auscultatory abnormalities on physical examination, and/or increased bronchitic markings or consolidation on a chest radiograph respiratory exacerbation. The primary outcome of this study was change in cough diary scores(week two compared to baseline) and this score was a validated scoring system (<LINK REF="REF-Chang-1998a" TYPE="REFERENCE">Chang 1998a</LINK>). Details of the study are in <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and some aspects are also described below. The authors of the study used the term airway malacia so we have used this term accordingly along with tracheomalacia. </P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2012-08-28 13:13:29 +0100" MODIFIED_BY="[Empty name]">
<P>We have added one of the more recent non-controlled studies to <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> (<LINK REF="STD-Gallagher-2011" TYPE="STUDY">Gallagher 2011</LINK>). It was a retrospective study (hospital chart review) comparing the treatment results of ipratropium bromide in children with tracheomalacia. The authors reported that 32 out of 52 children (for whom complete data were available) diagnosed with tracheomalacia and treated with ipratropium bromide after having been referred for specialist care, had improvement in their symptoms following treatment with ipratropium bromide.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2012-09-05 14:08:35 +0100" MODIFIED_BY="[Empty name]">
<P>Overall we assessed the sole included study (<LINK REF="STD-Boogaard-2009" TYPE="STUDY">Boogaard 2009</LINK>) to have a low risk of bias as detailed in the 'Risk of bias' table and summarised in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>. The following 'Risk of bias' domains refer to the sole study (<LINK REF="STD-Boogaard-2009" TYPE="STUDY">Boogaard 2009</LINK>) included in this review.</P>
<ALLOCATION MODIFIED="2012-08-28 13:13:38 +0100" MODIFIED_BY="[Empty name]">
<P>Randomisation was done in the pharmacy using a computer-generated blocked randomisation list prepared by a statistician. The study medication was prepared by a hospital pharmacist.</P>
</ALLOCATION>
<BLINDING MODIFIED="2012-08-28 13:13:39 +0100" MODIFIED_BY="[Empty name]">
<P>Study medication and placebo vials had identical appearance and smell. The parents, children, pulmonologists and trial co-ordinator remained unaware of the treatment assignment.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2012-09-05 14:08:35 +0100" MODIFIED_BY="[Empty name]">
<P>The number of participants withdrawn (one in the placebo group before the study drug was given, and one in the nebulised rhDNase group after the first dose of the study drug) and those who did not fill in their cough diary scores (one in each group) were reported for both nebulised rhDNase and placebo groups.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2012-05-14 12:48:34 +0100" MODIFIED_BY="[Empty name]">
<P>There was no suggestion that selective reporting had occurred.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2012-05-14 12:56:29 +0100" MODIFIED_BY="[Empty name]">
<P>The study was sponsored by pharmaceutical companies but reportedly they neither had influence on the design of the study, on the analysis of the study data nor in the publication of the results. </P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2012-09-05 14:08:35 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Primary outcome</HEADING>
<P>The primary outcome for the review was the proportion of participants who were not cured or not substantially improved at follow-up (clinical failure). Authors did not define this and hence from the raw data provided by Dr Boogaard, we calculated the number of children with clinical failure at follow-up. Based on previous published studies (<LINK REF="REF-Chang-1998b" TYPE="REFERENCE">Chang 1998b</LINK>; <LINK REF="REF-Chang-2012" TYPE="REFERENCE">Chang 2012</LINK>; <LINK REF="REF-Marchant-2012" TYPE="REFERENCE">Marchant 2012</LINK>), we defined clinical failure as less than 75% improvement in average daytime and night time cough diary scores at two weeks. We took the average of daytime and night time cough diary scores in the first two days of the study and compared it with the average of night time and daytime cough diary scores on day 13 and day 14. For one participant a cough diary score was not available for day 13 and so we used days 12 and 14 for this calculation. Another participant had daytime data missing for day 14, and so we used days 12 and 13 for this estimation. As depicted in (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>), 12 participants out of 21 were not cured or significantly improved at two weeks in the placebo group, compared to 11 participants out of 17 in the nebulised rhDNase group. There was no significant difference between the groups (OR 1.38; 95% CI 0.37 to 5.14; <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Change in cough score from baseline</HEADING>
<P>Mean changes in daytime cough diary score (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>) from baseline was better in the placebo group compared to those on nebulised rhDNase treatment, but the difference between groups was not statistically significant (mean difference (MD) 0.70; 95% CI -0.19 to 1.59). The change in night time scores (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>) significantly favoured the placebo group (MD 1.00; 95% CI 0.17 to 1.83, P = 0.02; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
<P>There was a significant (P = 0.02) difference between groups for visual analogue scores (VAS) of night time cough (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>) favouring the placebo group (MD 23.00; 95% CI 3.86 to 42.14), but there was no significant difference between groups for daytime score (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>) (MD 15.70; 95% CI -3.33 to 34.73).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Need for antibiotics</HEADING>
<P>Antibiotics were started in 5 of 17 (29%) children in the nebulised rhDNase group and in 8 of 21 (38%) children in the placebo group during the two week treatment period, (MD 9%; 95% CI -21% to 39%, P = 0.58).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other scores</HEADING>
<P>
<LINK REF="STD-Boogaard-2009" TYPE="STUDY">Boogaard 2009</LINK> also described VAS for daytime dyspnoea, night time dyspnoea (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>), and for difficulty in expectorating sputum (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>). These outcomes all improved significantly in both the nebulised rhDNase and placebo groups during the treatment period; the difference between the nebulised rhDNase and placebo favoured the placebo group, but these differences were not statistically significant.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Lung function</HEADING>
<P>The forced vital capacity (FVC) percentage predicted improved significantly in the placebo group but worsened in the nebulised rhDNase group (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>; <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>). The difference between the groups was at borderline significance (MD 8.80; 95% CI -0.05 to 17.80, P = 0.05). The forced expiratory volume in one second (FEV<SUB>1)</SUB> percentage predicted also improved (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>) in the placebo group as compared to the nebulised rhDNase group, but there was no significant difference between the groups (MD 9.20; CI -0.55 to 18.95, P = 0.06; <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2012-09-05 14:08:35 +0100" MODIFIED_BY="[Empty name]">
<P> </P>
<SUMMARY_OF_RESULTS MODIFIED="2012-09-05 14:08:35 +0100" MODIFIED_BY="[Empty name]">
<P>This review update is limited to a single study eligible for inclusion. Nebulised recombinant human deoxyribonuclease (rhDNase) did not improve and likely worsened respiratory symptoms when used during lower respiratory tract infections (LRTIs) in children with airway malacia. The data from this review were different to that published in the paper as we did not adjust for baseline imbalance. The children in the nebulised rhDNase group were symptomatic for seven days as compared to three days for placebo. Also, at baseline the placebo group showed lower lung function, and higher visual analogue scores (VAS) for night time cough and night time dyspnoea than did the nebulised rhDNase group. There were no other significant differences between groups at baseline. Hence, we did not adjust for baseline. The likely harm from nebulised rhDNase which was found in our review, was not evident in the published paper after adjusting for baseline (<LINK REF="STD-Boogaard-2009" TYPE="STUDY">Boogaard 2009</LINK>).</P>
<P>
<LINK REF="STD-Boogaard-2009" TYPE="STUDY">Boogaard 2009</LINK> postulated that dynamic airway collapse during coughing in children with airway malacia results in airway obstruction and impaired mucociliary clearance, and expected a beneficial effect of nebulised rhDNAse during LRTIs. However, we found the reverse. There are several possible explanations for the lack of beneficial effect of nebulised rhDNase in this study compared to that for children with cystic fibrosis (CF). One reason is the difference between the physical characteristics of mucous produced in children with CF (in CF large polymers predominate in the airway secretions; these polymers include deoxyribonucleic acid (DNA), filamentous actin, proteoglycans, and bio films, which in combination with bacteria and inflammatory cells constitute sputum) and children with primary tracheomalacia (<LINK REF="REF-Voynow-2009" TYPE="REFERENCE">Voynow 2009</LINK>). The mucous produced in children with airway malacia is likely similar to normal children. Unlike children with CF, the reduced mucous clearance in children with airway malacia is likely related to airway mechanics. The quality of sputum can be measured by different properties like dynamic viscoelasticity, wettability, cohesivity, interfacial (surface) tension, solids composition, Interleukin 8 and DNA content (<LINK REF="REF-Rubin-2007" TYPE="REFERENCE">Rubin 2007</LINK>). The rheologic properties that favour mucociliary clearance appear to hinder cough clearance and vice versa (<LINK REF="REF-Rogers-2006" TYPE="REFERENCE">Rogers 2006</LINK>). Thus the use of nebulised rhDNAse that alters sputum cohesiveness can impair airway clearance. This review highlights the fact that some of the interventions (like nebulised rhDNase) advocated by some for use in children with primary tracheomalacia are not efficacious or even potentially harmful. The non-beneficial and likely harmful effect of nebulised rhDNase we found in our review is similar to that described in the detrimental effect of nebulised rhDNase when used in adults with non-CF bronchiectasis (<LINK REF="REF-Crockett-2001" TYPE="REFERENCE">Crockett 2001</LINK>).</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2012-09-05 14:08:35 +0100" MODIFIED_BY="[Empty name]">
<P>For determining the primary outcome in our review, we averaged the scores over the first two days (for baseline) and the last two days (for final score). This was done as there is a day to day variability in cough diary cards and thus taking an average at the start and at the end (as done in our various studies on cough such as <LINK REF="REF-Chang-2010" TYPE="REFERENCE">Chang 2010</LINK> and <LINK REF="REF-Marchant-2012" TYPE="REFERENCE">Marchant 2012</LINK>) is arguably more robust. Furthermore, when we used only the first and last day's data, the difference in results of clinical failure remained statistically insignificant.</P>
<P>The single study on nebulised rhDNase cannot be applied to the effect of other mucolytics for airway malacia. This review has highlighted the fact that, although there are many medical and surgical therapies being used for the management of children with tracheomalacia, there remains a paucity in high quality data to support any single intervention. Although the review has shown that nebulised rhDNase is not useful as a medical therapy in children with airway malacia, this review is not a meta-analysis of different types of treatment options for tracheomalacia as there are no published RCTs. This review highlights the need to provide evidence based answers to this query.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2012-05-19 12:16:35 +0100" MODIFIED_BY="[Empty name]">
<P>There is only a single study in this review and hence quality of evidence is substantially limited.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2012-08-28 13:16:04 +0100" MODIFIED_BY="[Empty name]">
<P>The Cochrane Airways Group conducted an extensive search for RCTs in children with airway malacia. Two authors independently screened the searches and identified one study for inclusion. We identified the study itself as having overall low risk of bias. We have contacted the original investigators who kindly provided the raw data for calculation of clinical failure.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2012-08-28 13:16:14 +0100" MODIFIED_BY="[Empty name]">
<P>There are numerous cohort descriptive studies with varying numbers of patients that reported on a variety of interventions (mainly surgical) to increase the airway calibre. Most of these children managed surgically had presumably the severe end of the clinical spectrum, with life-threatening apnoea episodes. These cohort studies (see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>) have highlighted the importance of interventions in terms of clinical improvement. However these surgical procedures (tracheopexy, aortopexy and/or stenting) are not universally successful and have associated morbidity and mortality (<LINK REF="REF-Valerie-2005" TYPE="REFERENCE">Valerie 2005</LINK>). Continuous positive airway pressure (CPAP) alters forced expiratory flow in infants, but the authors did not describe clinical correlates (<LINK REF="STD-Davis-1998" TYPE="STUDY">Davis 1998</LINK>). There are no studies that quantitatively defined severity, either anatomically or clinically. Also, when tracheomalacia is associated with a vascular compression, surgical correction of the vascular compression alleviates major respiratory symptoms in most (68%) but not in a significant number of children (<LINK REF="REF-Benjamin-1976" TYPE="REFERENCE">Benjamin 1976</LINK>; <LINK REF="REF-Bonnard-2003" TYPE="REFERENCE">Bonnard 2003</LINK>).</P>
<P>Physiological measurement studies of lung function have shown short-term benefits in function in lung mechanics and improvement in spirometric parameters for selective children managed with surgical intervention (<LINK REF="REF-Zinman-1995" TYPE="REFERENCE">Zinman 1995</LINK>) and CPAP (<LINK REF="STD-Davis-1998" TYPE="STUDY">Davis 1998</LINK>). However there are no quantitative assessments of severity of the tracheomalacia at the entry or end point. Interpretation of lung function may be limited unless paired (pre- and post-intervention) data are obtained, as children with these airway abnormalities may have reduced lung growth (<LINK REF="REF-Agrawal-1999" TYPE="REFERENCE">Agrawal 1999</LINK>). At the mild end of the spectrum there are no studies that have assessed the disease impact, assessed the management of intercurrent respiratory illness or symptoms associated with tracheomalacia, nor supported any treatment for it.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2012-09-05 14:08:35 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2012-09-05 14:08:35 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Based on a single randomised trial, it is not possible to make meaningful recommendations for the routine use of any therapies for intrinsic tracheomalacia. Results of a single trial show that nebulised rhDNase appears not to be efficacious and likely harmful when used during a respiratory exacerbation. The decision to subject a child to surgical and/or medical based therapies will have to be made on an individual basis, with careful consideration of the risk-benefit ratio for each individual situation.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2012-08-28 13:16:44 +0100" MODIFIED_BY="[Empty name]">
<P>It is unlikely that any RCT on surgery for children with life-threatening illness associated with tracheomalacia will ever be available. For those with less severe disease, RCTs on interventions currently used by many respiratory physicians such as early use of antibiotics and chest physiotherapy are clearly needed. Other possible interventions include different mucolytics (such as hypertonic saline) and anti-inflammatories such as corticosteroids. Such trials should be parallel double-blind studies and outcomes should include correlation with measurements of the trachea and physiological based measurements in addition to clinical outcomes.<BR/>
</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2012-06-12 15:39:18 +0100" MODIFIED_BY="[Empty name]">
<P>We thank Toby Lasserson and Chris Cates from the Airways Group for their advice, supportive role and comments to the protocol and review. For the update we also thank Emma Welsh for her support. We are also very grateful to Elizabeth Stovold for performing the relevant searches over many years and for obtaining the articles.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2012-08-28 13:16:47 +0100" MODIFIED_BY="[Empty name]">
<P>IBM: formulation and writing of protocol.</P>
<P>AC: initiation, formulation and writing of protocol, review and selection of studies from the search, data extraction and writing and updating the review.</P>
<P>VG: updated the review, entered data in the updated review and contacted the original investigator of the included study for raw data.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2012-09-05 13:53:09 +0100" MODIFIED_BY="[Empty name]">
<P>The inclusion criteria was children under 15 years old with tracheomalacia, but we included a trial in which the oldest child enrolled was 15.5 years (<LINK REF="STD-Boogaard-2009" TYPE="STUDY">Boogaard 2009</LINK>).</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2012-09-05 14:08:35 +0100" MODIFIED_BY="Emma Jackson">
<STUDIES MODIFIED="2012-09-05 14:08:35 +0100" MODIFIED_BY="Emma Jackson">
<INCLUDED_STUDIES MODIFIED="2012-08-28 13:18:49 +0100" MODIFIED_BY="Emma Jackson">
<STUDY DATA_SOURCE="PUB" ID="STD-Boogaard-2009" MODIFIED="2012-08-28 13:18:49 +0100" MODIFIED_BY="Emma Jackson" NAME="Boogaard 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-08-28 13:18:49 +0100" MODIFIED_BY="Emma Jackson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boogaard R, de Jongste JC, Vaessen-Verberne A, Hop WCJ, Merkus PJ</AU>
<TI>Recombinant human DNase in children with airway malacia and lower respiratory tract infection</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2009</YR>
<VL>44</VL>
<NO>10</NO>
<PG>962&#8211;69</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2012-09-05 14:08:35 +0100" MODIFIED_BY="Emma Jackson">
<STUDY DATA_SOURCE="PUB" ID="STD-Abdel_x002d_Rahman-2002" MODIFIED="2008-04-17 15:18:22 +0100" MODIFIED_BY="[Empty name]" NAME="Abdel-Rahman 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abdel-Rahman U, Ahrens P, Fieguth HG, Kitz R, Heller K, Moritz A</AU>
<TI>Surgical treatment of tracheomalacia by bronchoscopic monitored aortopexy in infants and children</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>2002</YR>
<VL>74</VL>
<NO>2</NO>
<PG>315-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Corbally-1993" MODIFIED="2008-04-17 15:18:16 +0100" MODIFIED_BY="[Empty name]" NAME="Corbally 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Corbally MT, Spitz L, Kiely E, Brereton RJ, Drake DP</AU>
<TI>Aortopexy for tracheomalacia in oesophageal anomalies</TI>
<SO>European Journal of Pediatric Surgery</SO>
<YR>1993</YR>
<VL>3</VL>
<NO>5</NO>
<PG>264-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davis-1998" MODIFIED="2012-08-28 13:18:57 +0100" MODIFIED_BY="[Empty name]" NAME="Davis 1998" YEAR="1998">
<REFERENCE MODIFIED="2012-08-28 13:18:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davis S, Jones M, Kisling J, Angelicchio C, Tepper RS</AU>
<TI>Effect of continuous positive airway pressure on forced expiratory flows in infants with tracheomalacia</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1998</YR>
<VL>158</VL>
<NO>1</NO>
<PG>148-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Filler-1993" MODIFIED="2012-08-28 14:23:29 +0100" MODIFIED_BY="Emma Jackson" NAME="Filler 1993" YEAR="1993">
<REFERENCE MODIFIED="2012-08-28 14:23:29 +0100" MODIFIED_BY="Emma Jackson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Filler RM, Forte V, Chait P, Weber TR, Othersen HB, Tracy TF, et al</AU>
<TI>Tracheobronchial stenting for the treatment of airway obstruction</TI>
<SO>Journal of Pediatric Surgery</SO>
<YR>1993</YR>
<VL>33</VL>
<NO>2</NO>
<PG>304-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gallagher-2011" MODIFIED="2012-08-28 13:19:02 +0100" MODIFIED_BY="Emma Jackson" NAME="Gallagher 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-08-28 13:19:02 +0100" MODIFIED_BY="Emma Jackson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gallagher T, Maturo S, Fracchia S, Hartnick C</AU>
<TI>An analysis of children with tracheomalacia treated with ipratropium bromide (Atrovent)</TI>
<SO>Laryngoscope</SO>
<YR>2011</YR>
<VL>121</VL>
<NO>Suppl 4</NO>
<PG>S211</PG>
<IDENTIFIERS MODIFIED="2012-04-23 12:26:24 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McCarthy-1997" MODIFIED="2008-04-17 15:18:39 +0100" MODIFIED_BY="[Empty name]" NAME="McCarthy 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McCarthy JF, Hurley JP, Neligan MC, Wood AE</AU>
<TI>Surgical relief of tracheobronchial obstruction in infants and children</TI>
<SO>European Journal of Cardio-Thoracic Surgery</SO>
<YR>1997</YR>
<VL>11</VL>
<NO>6</NO>
<PG>1017-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nicolai-2001" MODIFIED="2008-04-17 15:18:44 +0100" MODIFIED_BY="[Empty name]" NAME="Nicolai 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nicolai T, Huber RM, Reiter K, Merkenschlager A, Hautmann H, Mantel K</AU>
<TI>Metal airway stent implantation in children: follow-up of seven children</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2001</YR>
<VL>31</VL>
<NO>4</NO>
<PG>289-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vazquez_x002d_Jimenez-2001" MODIFIED="2012-09-05 14:08:35 +0100" MODIFIED_BY="Emma Jackson" NAME="Vazquez-Jimenez 2001" YEAR="2001">
<REFERENCE MODIFIED="2012-09-05 14:08:35 +0100" MODIFIED_BY="Emma Jackson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vazquez-Jimenez JF, Sachweh JS, Liakopoulos OJ, Hugel W, Holzki J, von Bernuth G, et al</AU>
<TI>Aortopexy in severe tracheal instability: short-term and long-term outcome in 29 infants and children</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>2001</YR>
<VL>72</VL>
<NO>6</NO>
<PG>1898-901</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vinograd-1994" MODIFIED="2008-04-17 15:18:56 +0100" MODIFIED_BY="[Empty name]" NAME="Vinograd 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vinograd I, Klin B, Efrati Y, Barr J, Behar M, Eshel G</AU>
<TI>Airway obstruction in neonates and children: surgical treatment</TI>
<SO>Journal of Cardiovascular Surgery</SO>
<YR>1994</YR>
<VL>35</VL>
<NO>6 Suppl 1</NO>
<PG>7-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2012-04-15 13:12:51 +0100" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2012-09-05 14:08:35 +0100" MODIFIED_BY="Emma Jackson">
<ADDITIONAL_REFERENCES MODIFIED="2012-09-05 14:08:35 +0100" MODIFIED_BY="Emma Jackson">
<REFERENCE ID="REF-Agrawal-1999" NAME="Agrawal 1999" TYPE="JOURNAL_ARTICLE">
<AU>Agrawal L, Beardsmore CS, MacFadyen UM</AU>
<TI>Respiratory function in childhood following repair of oesophageal atresia and tracheoesophageal fistula</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1999</YR>
<VL>81</VL>
<NO>5</NO>
<PG>404-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Austin-2003" NAME="Austin 2003" TYPE="JOURNAL_ARTICLE">
<AU>Austin J, Ali T</AU>
<TI>Tracheomalacia and bronchomalacia in children: pathophysiology, assessment, treatment and anaesthesia management</TI>
<SO>Paediatric Anaesthesia</SO>
<YR>2003</YR>
<VL>13</VL>
<NO>1</NO>
<PG>3-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Beasley-1998" NAME="Beasley 1998" TYPE="JOURNAL_ARTICLE">
<AU>Beasley SW, Qi BQ</AU>
<TI>Understanding tracheomalacia</TI>
<SO>Journal of Paediatrics and Child Health</SO>
<YR>1998</YR>
<VL>34</VL>
<NO>3</NO>
<PG>209-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Benjamin-1976" NAME="Benjamin 1976" TYPE="JOURNAL_ARTICLE">
<AU>Benjamin B, Cohen D, Glasson M</AU>
<TI>Tracheomalacia in association with congenital tracheoesophageal fistula</TI>
<SO>Surgery</SO>
<YR>1976</YR>
<VL>79</VL>
<NO>5</NO>
<PG>504-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bibi-2001" MODIFIED="2012-09-05 14:08:34 +0100" MODIFIED_BY="Emma Jackson" NAME="Bibi 2001" TYPE="JOURNAL_ARTICLE">
<AU>Bibi H, Khvolis E, Shoseyov D, Ohaly M, Ben Dor D, London D, et al</AU>
<TI>The prevalence of gastroesophageal reflux in children with tracheomalacia and laryngomalacia</TI>
<SO>Chest</SO>
<YR>2001</YR>
<VL>119</VL>
<NO>2</NO>
<PG>409-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bonnard-2003" NAME="Bonnard 2003" TYPE="JOURNAL_ARTICLE">
<AU>Bonnard A, Auber F, Fourcade L, Marchac V, Emond S, Revillon Y</AU>
<TI>Vascular ring abnormalities: a retrospective study of 62 cases</TI>
<SO>Journal of Pediatric Surgery</SO>
<YR>2003</YR>
<VL>38</VL>
<NO>4</NO>
<PG>539-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boogaard-2005" MODIFIED="2012-08-28 13:19:11 +0100" MODIFIED_BY="Emma Jackson" NAME="Boogaard 2005" TYPE="JOURNAL_ARTICLE">
<AU>Boogaard R, Huijsmans SH, Pijnenburg MW, Tiddens HA, de Jongste JC, Merkus PJ</AU>
<TI>Tracheomalacia and bronchomalacia in children: incidence and patient characteristics</TI>
<SO>Chest</SO>
<YR>2005</YR>
<VL>128</VL>
<NO>5</NO>
<PG>3391&#8211;7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cates-2003" MODIFIED="2012-09-05 14:08:35 +0100" MODIFIED_BY="Emma Jackson" NAME="Cates 2003" TYPE="COMPUTER_PROGRAM">
<TI>Visual Rx. Online NNT Calculator</TI>
<YR>2003</YR>
<PB>Cates C</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chang-1998a" MODIFIED="2012-08-24 05:23:46 +0100" MODIFIED_BY="Emma Jackson" NAME="Chang 1998a" TYPE="JOURNAL_ARTICLE">
<AU>Chang AB, Newman RG, Carlin J, Phelan PD, Robertson CF</AU>
<TI>Subjective scoring of cough in children: parent-completed vs child-completed diary cards vs an objective method</TI>
<SO>European Respiratory Journal</SO>
<YR>1998</YR>
<VL>11</VL>
<NO>2</NO>
<PG>462-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chang-1998b" MODIFIED="2012-06-13 16:09:02 +0100" MODIFIED_BY="Emma Jackson" NAME="Chang 1998b" TYPE="JOURNAL_ARTICLE">
<AU>Chang AB, Phelan PD, Carlin J, Sawyer SM, Robertson CF</AU>
<TI>Randomised controlled trial of inhaled salbutamol and beclomethasone for recurrent cough</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1998</YR>
<VL>79</VL>
<PG>6-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chang-2004" NAME="Chang 2004" TYPE="JOURNAL_ARTICLE">
<AU>Chang AB, Moloney GE, Harms PJ, Masters IB</AU>
<TI>Endoscopic intratracheal carbon dioxide measurements during pediatric flexible bronchoscopy</TI>
<SO>Paediatric Anaesthesia</SO>
<YR>2004</YR>
<VL>14</VL>
<NO>8</NO>
<PG>650-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chang-2010" MODIFIED="2012-08-28 13:19:16 +0100" MODIFIED_BY="Anne Chang" NAME="Chang 2010" TYPE="JOURNAL_ARTICLE">
<AU>Chang AB, Robertson CF, van Asperen PP, Glasgow NJ, Masters IB, Mellis CM, et al</AU>
<TI>Can a management pathway for chronic cough in children improve clinical outcomes: protocol for a multicentre evaluation</TI>
<SO>Trials</SO>
<YR>2010</YR>
<VL>11</VL>
<PG>103</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chang-2012" MODIFIED="2012-09-05 14:08:34 +0100" MODIFIED_BY="Emma Jackson" NAME="Chang 2012" TYPE="OTHER">
<AU>Chang AB, Robertson CF, van Asperen PP, Glasgow NJ, Mellis CM, Masters IB, et al</AU>
<TI>A multi-centre study on chronic cough in children: burden and etiologies based on a standardized management pathway</TI>
<SO>Chest</SO>
<YR>2012 March 29 [Epub ahead of print]</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Crockett-2001" MODIFIED="2012-06-13 14:33:30 +0100" MODIFIED_BY="Emma Jackson" NAME="Crockett 2001" TYPE="COCHRANE_REVIEW">
<AU>Crockett AJ, Cranston JM, Latimer KM, Alpers JH</AU>
<TI>Mucolytics for bronchiectasis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2012-06-13 14:33:30 +0100" MODIFIED_BY="Emma Jackson">
<IDENTIFIER MODIFIED="2012-06-13 14:33:30 +0100" MODIFIED_BY="Emma Jackson" TYPE="DOI" VALUE="10.1002/14651858.CD001289"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Finder-1997" NAME="Finder 1997" TYPE="JOURNAL_ARTICLE">
<AU>Finder JD</AU>
<TI>Primary bronchomalacia in infants and children</TI>
<SO>Journal of Paediatrics</SO>
<YR>1997</YR>
<VL>130</VL>
<PG>59-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gormley-1999" MODIFIED="2008-04-17 15:17:24 +0100" MODIFIED_BY="[Empty name]" NAME="Gormley 1999" TYPE="JOURNAL_ARTICLE">
<AU>Gormley PK, Colreavy MP, Patil N, Woods AE</AU>
<TI>Congenital vascular anomalies and persistent respiratory symptoms in children</TI>
<SO>International Journal of Pediatric Otorhinolaryngology</SO>
<YR>1999</YR>
<VL>51</VL>
<NO>1</NO>
<PG>23-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2012-08-28 14:25:41 +0100" MODIFIED_BY="Emma J Welsh" NAME="Higgins 2011" TYPE="BOOK">
<AU>Higgins JPT, Green S, editors</AU>
<SO>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated March 2011]</SO>
<YR>2011</YR>
<PB>The Cochrane Collaboration, Available from www.cochrane-handbook.org</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Horvath-1992" MODIFIED="2012-09-05 14:08:34 +0100" MODIFIED_BY="Emma Jackson" NAME="Horvath 1992" TYPE="JOURNAL_ARTICLE">
<AU>Horvath P, Hucin B, Hruda J, Sulc J, Brezovsky P, Tuma S, et al</AU>
<TI>Intermediate to late results of surgical relief of vascular tracheobronchial compression</TI>
<SO>European Journal of Cardio-Thoracic Surgery</SO>
<YR>1992</YR>
<VL>6</VL>
<NO>7</NO>
<PG>366-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kovesi-2004" NAME="Kovesi 2004" TYPE="JOURNAL_ARTICLE">
<AU>Kovesi T, Rubin S</AU>
<TI>Long-term complications of congenital esophageal atresia and/or tracheoesophageal fistula</TI>
<SO>Chest</SO>
<YR>2004</YR>
<VL>126</VL>
<NO>3</NO>
<PG>915-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marchant-2012" MODIFIED="2012-08-28 13:19:28 +0100" MODIFIED_BY="Emma Jackson" NAME="Marchant 2012" TYPE="OTHER">
<AU>Marchant JM, Masters IB, Champion A, Petsky HL, Chang AB</AU>
<TI>Randomised controlled trial of amoxycillin-clavulanate in children with chronic wet cough</TI>
<SO>Thorax</SO>
<YR>2012 May 24 [Epub ahead of print]</YR>
<IDENTIFIERS MODIFIED="2012-06-13 14:52:03 +0100" MODIFIED_BY="Emma Jackson">
<IDENTIFIER MODIFIED="2012-06-13 14:52:03 +0100" MODIFIED_BY="Emma Jackson" TYPE="DOI" VALUE="10.1136/thoraxjnl-2011-201506"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Masters-2002" MODIFIED="2012-08-28 13:19:34 +0100" MODIFIED_BY="Emma Jackson" NAME="Masters 2002" TYPE="JOURNAL_ARTICLE">
<AU>Masters IB, Chang AB, Patterson L, Wainwright C, Buntain H, Dean BW, et al</AU>
<TI>Series of laryngomalacia, tracheomalacia, and bronchomalacia disorders and their associations with other conditions in children</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2002</YR>
<VL>34</VL>
<NO>3</NO>
<PG>189-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Masters-2009" MODIFIED="2012-06-19 11:16:42 +0100" MODIFIED_BY="Emma Jackson" NAME="Masters 2009" TYPE="JOURNAL_ARTICLE">
<AU>Masters IB, Chang AB</AU>
<TI>Tracheobronchomalacia in children</TI>
<SO>Expert Review of Respiratory Medicine</SO>
<YR>2009</YR>
<VL>3</VL>
<PG>425-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Midulla-2003" MODIFIED="2012-09-05 14:08:34 +0100" MODIFIED_BY="Emma Jackson" NAME="Midulla 2003" TYPE="JOURNAL_ARTICLE">
<AU>Midulla F, de Blic J, Barbato A, Bush A, Eber E, Kotecha S, et al</AU>
<TI>Flexible endoscopy of paediatric airways</TI>
<SO>European Respiratory Journal</SO>
<YR>2003</YR>
<VL>22</VL>
<NO>4</NO>
<PG>698-708</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2011" MODIFIED="2012-08-28 13:19:39 +0100" MODIFIED_BY="[Empty name]" NAME="RevMan 2011" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2011</YR>
<EN>5.1</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rogers-2006" MODIFIED="2012-08-29 03:23:22 +0100" MODIFIED_BY="Emma Jackson" NAME="Rogers 2006" TYPE="BOOK_SECTION">
<AU>Rogers DF, Rubin BK</AU>
<TI>Mucolytics for COPD</TI>
<SO>Chronic Obstructive Lung Disease</SO>
<YR>2006</YR>
<PG>756&#8211;68</PG>
<ED>Stockley RA, Rennard S, Rabe K,Celli B</ED>
<PB>Blackwell Publishing, Oxford, UK</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rubin-2007" MODIFIED="2012-08-28 13:19:59 +0100" MODIFIED_BY="Emma Jackson" NAME="Rubin 2007" TYPE="JOURNAL_ARTICLE">
<AU>Rubin BK</AU>
<TI>Mucolytics, expectorants, and mucokinetic medications</TI>
<SO>Respiratory Care</SO>
<YR>2007</YR>
<VL>52</VL>
<NO>7</NO>
<PG>859-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sanchez-2012" MODIFIED="2012-06-19 11:17:58 +0100" MODIFIED_BY="Emma Jackson" NAME="Sanchez 2012" TYPE="JOURNAL_ARTICLE">
<AU>Sanchez MO, Greer MC, Masters IB, Chang AB</AU>
<TI>A comparison of fluoroscopic airway screening with flexible bronchoscopy for diagnosing tracheomalacia</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2012</YR>
<VL>47</VL>
<PG>63-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thomson-2002" MODIFIED="2012-08-28 13:20:03 +0100" MODIFIED_BY="[Empty name]" NAME="Thomson 2002" TYPE="JOURNAL_ARTICLE">
<AU>Thomson F, Masters IB, Chang AB</AU>
<TI>Persistent cough in children and the overuse of medications</TI>
<SO>Journal of Paediatrics and Child Health</SO>
<YR>2002</YR>
<VL>38</VL>
<NO>6</NO>
<PG>578-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Valerie-2005" NAME="Valerie 2005" TYPE="JOURNAL_ARTICLE">
<AU>Valerie EP, Durrant AC, Forte V, Wales P, Chait P, Kim PC</AU>
<TI>A decade of using intraluminal tracheal/bronchial stents in the management of tracheomalacia and/or bronchomalacia: is it better than aortopexy?</TI>
<SO>Journal of Pediatric Surgery</SO>
<YR>2005</YR>
<VL>40</VL>
<NO>6</NO>
<PG>904-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-Son-1993" MODIFIED="2012-09-05 14:08:34 +0100" MODIFIED_BY="Emma Jackson" NAME="van Son 1993" TYPE="JOURNAL_ARTICLE">
<AU>van Son JA, Julsrud PR, Hagler DJ, Sim EK, Pairolero PC, Puga FJ, et al</AU>
<TI>Surgical treatment of vascular rings: the Mayo Clinic experience</TI>
<SO>Mayo Clinic Proceedings</SO>
<YR>1993</YR>
<VL>68</VL>
<NO>11</NO>
<PG>1056-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Voynow-2009" MODIFIED="2012-08-28 13:20:10 +0100" MODIFIED_BY="Emma Jackson" NAME="Voynow 2009" TYPE="JOURNAL_ARTICLE">
<AU>Voynow JA, Rubin BK</AU>
<TI>Mucins, Mucus, and Sputum</TI>
<SO>Chest</SO>
<YR>2009</YR>
<VL>135</VL>
<PG>505-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wood-1997" NAME="Wood 1997" TYPE="JOURNAL_ARTICLE">
<AU>Wood RE</AU>
<TI>Localised tracheomalacia or bronchomalacia in children with intractable cough</TI>
<SO>Journal of Paediatrics</SO>
<YR>1997</YR>
<VL>116</VL>
<PG>404-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wright-2003" NAME="Wright 2003" TYPE="JOURNAL_ARTICLE">
<AU>Wright CD</AU>
<TI>Tracheomalacia</TI>
<SO>Chest Surgery Clinics of North America</SO>
<YR>2003</YR>
<VL>13</VL>
<NO>2</NO>
<PG>349-57, viii</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zinman-1995" NAME="Zinman 1995" TYPE="JOURNAL_ARTICLE">
<AU>Zinman R</AU>
<TI>Tracheal stenting improves airway mechanics in infants with tracheobronchomalacia</TI>
<SO>Pediatric Pulmonology</SO>
<YR>1995</YR>
<VL>19</VL>
<NO>5</NO>
<PG>275-81</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2012-06-13 15:48:17 +0100" MODIFIED_BY="Emma Jackson">
<REFERENCE ID="REF-Masters-2005" MODIFIED="2012-06-13 15:48:14 +0100" MODIFIED_BY="Emma Jackson" NAME="Masters 2005" TYPE="COCHRANE_REVIEW">
<AU>Masters IB, Chang AB</AU>
<TI>Interventions for primary (intrinsic) tracheomalacia in children</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2012-06-13 15:48:14 +0100" MODIFIED_BY="Emma Jackson">
<IDENTIFIER MODIFIED="2012-06-13 15:48:02 +0100" MODIFIED_BY="Emma Jackson" TYPE="DOI" VALUE="10.1002/14651858.CD005304.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2012-08-28 13:17:59 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2012-08-28 13:17:29 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2012-08-28 13:17:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Boogaard-2009">
<CHAR_METHODS MODIFIED="2012-08-28 13:16:54 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Prospective, double-blind, parallel group randomised controlled study</LI>
<LI>Compared effect of inhaled rhDNase with placebo on respiratory symptoms, the need for antibiotics, and lung function</LI>
<LI>Outpatient setting in Erasmus MC-Sophia Children&#8217;s Hospital and Amphia Hospital, Breda between September 2005 and March 2008</LI>
<LI>Children already diagnosed with malacia according to accepted guidelines (described in the study)</LI>
<LI>Children with airway malacia and recurrent LRTIs from outpatient department, were instructed to contact the hospital when they developed symptoms suggestive of a LRTI</LI>
<LI>Patients were recruited by paediatric pulmonologists at the outpatient department within 2 days of this contact</LI>
<LI>Allocation sequence executed by the study co-ordinator based on the randomisation schedule prepared by the study statistician</LI>
<LI>The decision for investigations was up to the paediatric pulmonologist</LI>
<LI>Patients were re-evaluated by a paediatric pulmonologist after 1 (visit 2) and 2 weeks (visit 3)</LI>
<LI>The study co-ordinator contacted parents by telephone after 3 weeks</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-08-28 13:17:13 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>49 children screened for inclusion</LI>
<LI>5 did not have LRTI and 4 needed antibiotics</LI>
<LI>22 were assigned to the placebo group and 18 to the rhDNase group (total 40)</LI>
<LI>21 children received placebo and 17 children received rhDNase (20 females out of 38); one withdrawal in each group</LI>
<LI>Mean age in placebo group was 6.0 and 6.7 years in the rhDNase group. Inclusion criteria: children aged 2 to 18 years with airway malacia and symptoms of LRTI</LI>
<LI>Baseline demographic characteristics did not differ between the treatment groups</LI>
<LI>Exclusion criteria: need for antibiotics at initial presentation, chronic cardiopulmonary disease and neuromuscular disease</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-28 13:17:16 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>2.5 mg of rhDNase (2.5ml solution of 1 mg/mlL rhDNase) or 2.5 mg placebo (2.5mL sodium chloride 0.9%), twice daily for 2 weeks</LI>
<LI>Study medication was administered with a Sidestream jet nebuliser using a PortaNeb Compressor</LI>
<LI>The first dose of study medication was administered in the outpatient department</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-08-28 13:17:11 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: change in symptom severity from baseline to second week of treatment, assessed with a cough diary score</P>
<P>Secondary outcomes:</P>
<UL>
<LI>need for an antibiotic course during the two-week treatment period</LI>
<LI>cough scores</LI>
<LI>severity of dyspnoea</LI>
<LI>ease of expectorating sputum</LI>
<LI>lung function</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>LRTI: lower respiratory tract infection<BR/>rhDNase: recombinant human deoxyribonuclease</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2012-08-28 13:17:59 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2012-08-28 13:17:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Abdel_x002d_Rahman-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-08-28 13:17:31 +0100" MODIFIED_BY="[Empty name]">
<P>Non-controlled study. Authors reported on effect of aortopexy on 16 infants and children with tracheomalacia. No intraoperative or postoperative mortality occurred and 13 (81%) had permanent relief of symptoms</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-08-28 13:17:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Corbally-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-08-28 13:17:33 +0100" MODIFIED_BY="[Empty name]">
<P>Non-controlled study. Authors reported on 48 patients with repaired congenital oesophageal anomaly who underwent aortopexy for significant tracheomalacia. Indications for aortopexy included recurrent apnoea/cyanosis, near fatal episodes, recurrent respiratory distress and infection and worsening stridor. Aortopexy cured near fatal episodes in all patients and resulted in improvement of airway obstruction in 95%. The procedure failed in 2 patients due to unrecognised bronchomalacia and phrenic nerve palsy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-08-28 13:17:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Davis-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-08-28 13:17:35 +0100" MODIFIED_BY="[Empty name]">
<P>Non-controlled study. Continuous positive airway pressure (CPAP) was used to minimise airway collapse in infants with tracheomalacia. Forced expiratory flows increased with CPAP use</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-08-28 13:17:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Filler-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-08-28 13:17:38 +0100" MODIFIED_BY="[Empty name]">
<P>Non-controlled study. The authors reported on their five-year experience of inserting the Palmaz stent into infants and children who had a variety of major airway obstructions, including tracheomalacia in eight children. Granulation tissue developed over the stents in five of eight cases. Obstructing granulations were removed by scraping or balloon compression in three and resulted in earlier than the planned removal in two</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-08-28 13:17:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gallagher-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-08-28 13:17:40 +0100" MODIFIED_BY="[Empty name]">
<P>Non-controlled study. Authors retrospectively reviewed charts of 52 children with tracheomalacia and treated with ipratropium bromide after having been referred for specialist care. Mild tracheomalacia was diagnosed in 34 (65.3%) children while moderate tracheomalacia was seen in 18 (34.7%). Overall 32 (61.5%) children had improvement in their symptoms following treatment with ipratropium bromide</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-08-28 13:17:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McCarthy-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-08-28 13:17:43 +0100" MODIFIED_BY="[Empty name]">
<P>Non-controlled study. Twenty-four infants and children with various causes of airway obstruction including tracheomalacia. Hospital mortality was 8.7%, 19 (79.2%) patients were alive and symptom-free. The single most important predictor of mortality was the presence of associated cardiac anomalies</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-08-28 13:17:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nicolai-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-08-28 13:17:45 +0100" MODIFIED_BY="[Empty name]">
<P>Non-controlled study. Authors reported on 7 children with extreme structural central airway obstruction (six were mechanically ventilated). All patients showed marked improvement of their respiratory obstruction; six were weaned at least temporarily from ventilation. Three children are well and at home</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-08-28 13:17:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vazquez_x002d_Jimenez-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-08-28 13:17:58 +0100" MODIFIED_BY="[Empty name]">
<P>Non-controlled study. Authors reported on 29 children operated for tracheomalacia associated with oesophageal atresia. No early nor late mortality occurred. Surgery associated morbidity: reversible lesion of the phrenic nerve was observed in two patients, a pneumothorax in three, and secondary wound healing in one. In all but one patient symptoms improved markedly or disappeared within days or within the first three months postoperatively. An increased susceptibility to respiratory infections was observed in long-term follow-up of children</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-08-28 13:17:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vinograd-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-08-28 13:17:59 +0100" MODIFIED_BY="[Empty name]">
<P>Non-controlled study. Authors reported on surgical management (aortopexy) of 54 children with airway problems, of whom 20 had tracheomalacia. No operative deaths occurred</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2012-04-15 13:12:51 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2012-08-28 13:17:25 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2012-08-28 13:17:21 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-28 13:17:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Boogaard-2009">
<DESCRIPTION>
<P>Randomisation done in the pharmacy using a computer-generated blocked randomisation list prepared by statistician</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2012-08-28 13:17:21 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-28 13:17:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Boogaard-2009">
<DESCRIPTION>
<P>The study medication was prepared by hospital pharmacist and rhDNase and placebo vials had identical appearance and smell</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2012-08-28 13:17:22 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-08-28 13:17:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Boogaard-2009">
<DESCRIPTION>
<P>Throughout the study, parents, children, pulmonologists and trial co-ordinator remained unaware of the treatment assignment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2012-04-18 09:38:15 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-04-18 09:38:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boogaard-2009">
<DESCRIPTION>
<P>Both subjects and researchers were blinded to the outcomes measured but blinding by statistical team was not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2012-08-28 13:17:24 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-28 13:17:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Boogaard-2009">
<DESCRIPTION>
<P>No study data was available for one child from each group as they did not take the study medication or withdrew after randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2012-06-12 15:42:24 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-12 15:42:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Boogaard-2009">
<DESCRIPTION>
<P>No evidence of selective reporting found</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2012-08-28 13:17:25 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-28 13:17:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boogaard-2009">
<DESCRIPTION>
<P>Study funded by pharmaceutical companies but the companies did not have influence on the design of the study, analysis of the study data or writing of the manuscript</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2012-08-28 14:23:23 +0100" MODIFIED_BY="Emma J Welsh">
<SOF_TABLE ID="SOF-01" MODIFIED="2012-08-28 14:23:23 +0100" MODIFIED_BY="Grade Profiler" NO="1" READONLY="YES">
<TITLE MODIFIED="2012-05-25 13:09:38 +0100" MODIFIED_BY="Grade Profiler">Human deoxyribonuclease versus placebo for primary (intrinsic) tracheomalacia in children</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD COLSPAN="7">
<P>
<B>Human deoxyribonuclease versus placebo for primary (intrinsic) tracheomalacia in children</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> children with primary (intrinsic) tracheomalacia<BR/>
<B>Settings: </B>outpatient<BR/>
<B>Intervention:</B> human deoxyribonuclease</P>
<P>
<B>Control</B>: placebo<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>No. of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Human deoxyribonuclease versus placebo</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Clinical failure</B>
<BR/>Number of children with no significant improvement in cough diary scores at two weeks (average of day 13 to 14)<BR/>Follow-up: 2 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>57 per 100</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>65 per 100</B>
<BR/>(33 to 87)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 1.38 </B>
<BR/>(0.37 to 5.14)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>38<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>Low quality</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>These results should be interpreted with caution given there is only one study</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Daytime cough diary scores (change from baseline)</B>
<BR/>Follow-up: 2 weeks</P>
<P>On a scale of 0 to 5, 0 being no cough and 5 means unable to perform most usual activities due to coughing</P>
</TD>
<TD VALIGN="TOP">
<P>-1.7</P>
</TD>
<TD VALIGN="TOP">
<P>0.70 higher (-0.19 to 1.59)</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>38<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>Low quality</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>There was no significant difference in daytime cough diary scores in two groups</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Night time cough diary score (change from baseline)</B>
<BR/>Follow-up: 2 weeks</P>
<P>On a scale of 0 to 5, 0 being no cough and 5 means unable to perform most usual activities due to coughing</P>
</TD>
<TD VALIGN="TOP">
<P>-1.7</P>
</TD>
<TD VALIGN="TOP">
<P>1.00 higher (0.17 to 1.83)</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>38<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>Low quality</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>Night time cough diary scores significantly favoured the placebo group</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Night time VAS (change from baseline)</B>
</P>
<P>Follow-up: 2 weeks</P>
<P>VAS is a marked scale of 10 cm length, anchored by word descriptors at each end (e.g. 0 cm is absence of cough and 10 cm is continuous coughing). The child or parent places a mark on this line in the position that best represents their perception and the result is measured in mm from the anchor point i.e. scale of 0 to 100</P>
</TD>
<TD VALIGN="TOP">
<P>-36.7</P>
</TD>
<TD VALIGN="TOP">
<P>23.00 higher (3.86 to 42.14)</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>38</P>
<P>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>Low quality</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>Night time VAS significantly favoured the placebo group</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Difficulty expectorating sputum score (change from baseline)</B>
</P>
<P>Follow-up: 2 weeks</P>
<P>VAS is a marked scale of 10 cm length, anchored by word descriptors at each end. On a scale of 0 to 100, 0 would mean no difficulty in expectoration and 100 would mean unable to expectorate</P>
</TD>
<TD VALIGN="TOP">
<P>-35.6</P>
</TD>
<TD VALIGN="TOP">
<P>0.46 higher (-0.19 to 1.11)</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>38</P>
<P>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>Low quality</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The data supported the placebo but the CI is too wide</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Lung function: FVC % predicted (baseline to end point)</B>
</P>
<P>Follow-up: 2 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>-8.2%</P>
</TD>
<TD VALIGN="TOP">
<P>8.80% lower (-0.05 to 17.65)</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>27</P>
<P>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>Low quality</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The FVC % improved with placebo but worsened with rhDNase and the difference between two groups was of borderline significance</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Lung function: FEV<SUB>1</SUB> % predicted (baseline to end point)</B>
</P>
<P>Follow-up: 2 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>-10.8%</P>
</TD>
<TD VALIGN="TOP">
<P>9.20% lower (-0.55 to 18.95)</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>27</P>
<P>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>Low quality</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>FEV<SUB>1</SUB> % at end point improved more with placebo, but the CI was too wide to be of any significance</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI). The assumed risk for continuous data is the mean for the placebo group and corresponding risk is the mean difference. Since there was only one study in the review, assumed risk is not expressed as a range.<BR/>
<B>CI:</B> confidence interval;<B> FEV<SUB>1</SUB>
</B>: forced expiratory volume in one second; <B>FVC</B>: forced vital capacity; <B>OR:</B> odds ratio; <B>rhDNase</B>: recombinant human deoxyribonuclease; <B>VAS</B>: visual analogue score.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<BR/>
<SUP>1</SUP> These results come from a single study on a small number of participants and need confirmation in other, larger studies.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2012-05-30 13:59:03 +0100" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2012-08-29 03:01:29 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2012-08-29 03:01:29 +0100" MODIFIED_BY="Emma J Welsh" NO="1">
<NAME>Human deoxyribonuclease versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-06-16 12:32:00 +0100" MODIFIED_BY="Emma J Welsh" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="17" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Clinical failure (Number of children with no significant improvement in cough scores at two weeks</NAME>
<GROUP_LABEL_1>rhDNase</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>rhDNase</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.135542531487532" CI_START="0.36814513528181647" EFFECT_SIZE="1.375" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.7105863303062663" LOG_CI_START="-0.4339809339737034" LOG_EFFECT_SIZE="0.13830269816628146" MODIFIED="2012-05-24 15:40:09 +0100" MODIFIED_BY="Emma J Welsh" ORDER="10" O_E="0.0" SE="0.6723244767373876" STUDY_ID="STD-Boogaard-2009" TOTAL_1="17" TOTAL_2="21" VAR="0.452020202020202" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2012-06-16 12:32:00 +0100" MODIFIED_BY="Emma J Welsh" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="17" TOTAL_2="21" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Daytime cough diary scores (change from baseline)</NAME>
<GROUP_LABEL_1>rhDNase</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>rhDNase</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.5943263965015995" CI_START="-0.19432639650159955" EFFECT_SIZE="0.7" ESTIMABLE="YES" MEAN_1="-1.0" MEAN_2="-1.7" MODIFIED="2012-05-24 15:41:24 +0100" MODIFIED_BY="Emma J Welsh" ORDER="11" SD_1="1.6" SD_2="1.1" SE="0.4562973623780498" STUDY_ID="STD-Boogaard-2009" TOTAL_1="17" TOTAL_2="21" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.03" MODIFIED="2012-08-29 03:01:29 +0100" MODIFIED_BY="Emma J Welsh" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="17" TOTAL_2="21" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Night time cough diary score (change from baseline)</NAME>
<GROUP_LABEL_1>rhDNase</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>rhDNase</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.8276511066946335" CI_START="0.1723488933053664" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="-0.7" MEAN_2="-1.7" MODIFIED="2012-05-24 15:41:24 +0100" MODIFIED_BY="Emma J Welsh" ORDER="12" SD_1="1.1" SD_2="1.5" SE="0.42227873227418455" STUDY_ID="STD-Boogaard-2009" TOTAL_1="17" TOTAL_2="21" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.04" MODIFIED="2012-08-29 03:00:53 +0100" MODIFIED_BY="Emma J Welsh" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="50.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="17" TOTAL_2="21" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Daytime visual analogue score (change from baseline)</NAME>
<GROUP_LABEL_1>rhDNase</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>rhDNase</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="34.72643985532686" CI_START="-3.326439855326864" EFFECT_SIZE="15.7" ESTIMABLE="YES" MEAN_1="-16.2" MEAN_2="-31.9" MODIFIED="2012-05-24 15:41:24 +0100" MODIFIED_BY="Emma J Welsh" ORDER="13" SD_1="36.4" SD_2="18.5" SE="9.70754565155533" STUDY_ID="STD-Boogaard-2009" TOTAL_1="17" TOTAL_2="21" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2012-08-29 03:01:16 +0100" MODIFIED_BY="Emma J Welsh" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="17" TOTAL_2="21" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Night time visual analogue score (change from baseline)</NAME>
<GROUP_LABEL_1>rhDNase</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>rhDNase</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="42.143971241337724" CI_START="3.856028758662287" EFFECT_SIZE="23.000000000000004" ESTIMABLE="YES" MEAN_1="-13.7" MEAN_2="-36.7" MODIFIED="2012-05-24 15:41:24 +0100" MODIFIED_BY="Emma J Welsh" ORDER="14" SD_1="30.6" SD_2="29.1" SE="9.767511746309074" STUDY_ID="STD-Boogaard-2009" TOTAL_1="17" TOTAL_2="21" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2012-06-16 12:32:00 +0100" MODIFIED_BY="Emma J Welsh" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="17" TOTAL_2="21" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Night time dyspnoea score (change from baseline)</NAME>
<GROUP_LABEL_1>rhDNase</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>rhDNase</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="27.139477938320024" CI_START="-3.339477938320023" EFFECT_SIZE="11.9" ESTIMABLE="YES" MEAN_1="-7.1" MEAN_2="-19.0" MODIFIED="2012-05-24 15:41:31 +0100" MODIFIED_BY="Emma J Welsh" ORDER="15" SD_1="18.5" SD_2="29.1" SE="7.775386720637257" STUDY_ID="STD-Boogaard-2009" TOTAL_1="17" TOTAL_2="21" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.07" MODIFIED="2012-06-16 12:32:00 +0100" MODIFIED_BY="Emma J Welsh" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="115.91" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="17" TOTAL_2="21" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Difficulty expectorating sputum score (change from baseline)</NAME>
<GROUP_LABEL_1>rhDNase</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>rhDNase</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.1060411784778914" CI_START="-0.1911782305674628" EFFECT_SIZE="0.4574314739552143" ESTIMABLE="YES" MEAN_1="-20.8" MEAN_2="-35.6" MODIFIED="2012-05-24 15:41:31 +0100" MODIFIED_BY="Emma J Welsh" ORDER="16" SD_1="29.8" SD_2="33.1" SE="0.3309293995393934" STUDY_ID="STD-Boogaard-2009" TOTAL_1="17" TOTAL_2="21" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.08" MODIFIED="2012-06-16 12:32:00 +0100" MODIFIED_BY="Emma J Welsh" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="14" TOTAL_2="13" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Lung function: FVC % predicted</NAME>
<GROUP_LABEL_1>rhDNase</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>rhDNase</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="17.652396040931308" CI_START="-0.052396040931309784" EFFECT_SIZE="8.799999999999999" ESTIMABLE="YES" MEAN_1="0.6" MEAN_2="-8.2" MODIFIED="2012-05-24 15:41:38 +0100" MODIFIED_BY="Emma J Welsh" ORDER="17" SD_1="13.8" SD_2="9.4" SE="4.516611586109683" STUDY_ID="STD-Boogaard-2009" TOTAL_1="14" TOTAL_2="13" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.09" MODIFIED="2012-08-29 03:00:37 +0100" MODIFIED_BY="Emma J Welsh" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="14" TOTAL_2="13" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Lung function: FEV1 % predicted</NAME>
<GROUP_LABEL_1>rhDNase</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>rhDNase</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="18.946897995512387" CI_START="-0.5468979955123849" EFFECT_SIZE="9.200000000000001" ESTIMABLE="YES" MEAN_1="-1.6" MEAN_2="-10.8" MODIFIED="2012-05-24 15:41:38 +0100" MODIFIED_BY="Emma J Welsh" ORDER="18" SD_1="14.1" SD_2="11.7" SE="4.972998520582355" STUDY_ID="STD-Boogaard-2009" TOTAL_1="14" TOTAL_2="13" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2012-09-05 14:08:35 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2012-08-28 13:20:21 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: Review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEACAMAAABVk4iuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADAAMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdCQkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYAAJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkAmcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwzAP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8zzAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBmMzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNmzGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZM5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZzMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zMM//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP//2b//5n//8z///9BjlLGAAAcpElEQVR42u1da3Ab13U+fOwLgEjskqxFqdWYopp2Rv2ROpViyaJrg1YStUmcZJqZjOO8PFO5idNkOsk0iTvjOv1RO07s1vU4D9kzil9pM/Z4audh2ZLg2JDyoDrqdBqlGYcUVTki6IrcJSWCC2BBsPe1LzxIEAQg0D6fHsDee849dxff3nt3sR8OAALRNHSAjgcB0SRYnXgMEM0D0guB9EIgvRAIpBcC6YVAeiEQSC/EFUM3HoLGwsJDELhTj/TC+aDRKOLBQOC5hkB6IRBILwTSC4H02jAwW+6IaBK9EgRyJF2x6krt29YqsfXYKj2s4piobL1sII2aPnolk8lpabit9m0P6VWlscn+3/oc3T0t2S7YONq1YnI0JgsAA5qskNM5EVdl8jIWUegtXCcqRx1aqMiHbVVKMXNbUtQUrZNiDrVU9QQfGsg/M6JETeag2KROpU2KMmCtxomRE+Ot9h6Qba+dRK8q+pBgf2g5t3LjPm33gS0rGostUx/w2nLUUd8xokT8PrC4GmsJoF+TVbJfKVlW+0FaHEYetWLttV0CuBzNRzPkfXEqRl4SanqJbPQ9l5f7aGH6+GcGpy6NMuueWO7oTaRu3KF1iRenAoPAtvncEZ05zPUC3Kids/0ygF1ymt4Z7rPyCm0Vnjre47UDXVOwEM3PZcgow8aZvud4Obhx/+YEi/0SjT3H+8Xaou/i2n8tuo66klO3eX1gcS+Mc+uMmY8sAozG8kcXAE7kkUfNphddexXmALIzYF5Hts8Z9KUwbsySjdw1MJElr7PGyJ6zhraPeShOameO1A2CSV6cnUYhMOFIMKKxVqhxYWLQ9ssAtLO8VYl5wqQxMuK1A+MG2DOgXec29RERe9KNu7STxM7z2KIF9s7K0UgzWa8PEzBe8PpAYRmD3NrW2E5Kuf6dxHxnAXlUBY1SCiWSYBuXyOg1u71Q3JOk2/SfnGcvdIu8FYXsHyFU/KOP9Vxk0yE5/yXHs6QvvNDdSrpLaj5QHDzkGclHKrjMbl9a4n0QzkouEJf2icbeNBPwCXhDwDHQaQi0ZA4tFfYmYXab03FukPfHBYpjoKg342BoyhfI/7fCzKUAe02ga5uTZoWLfSlzb+Qy+VDJRQH5wK/nluK2wEleKHCSOftlj3Nb6nnEMzrhu9wKF/2LwxMk9nIw7ojJYy8EmxTeHYFu0k6PhHrsgPkJcWkpv0pn1My0divp8GM4TLVg7TX3KFktHz9q9/lF2WHop/PgDhhWS83VlPE8WZipA6BHAU5pzPKkbVLuk7HssOZZdu9Ia6zM5o3Y26GPLKBUB45F/OZ4OxTHZ+ycx0q1NPbPz5BCm8VW0q4PaUsnbf18eEBljKR90GDHL0I97gXt3/j5+evxm/ge/IDs8hl87KQlS/v5/SbMXz8YaPNUXu2ga66cnJ8ttd60X2YzmS1nCXnO9SvUcq5383fpxX+v/Gl/EJxbHCIfeDIu65f5mJtTaIzZuHR/1DMS7bB+bGJ96N4MlWLLZCW1yeCxf9/1IW1dS9p62b5ESCZfxW5A9Ml2+CbEvDrAW4rcxgLE9iuj8wD7ZORRk9dejVrA1XwTxLbrjWJ+9Mm+Rvbaef9TBq69Kq+9ukBrn35NLdVm98X/6Fp65ZF6o3xtNvPTRva6N/3VwFa24y1Pr2UtcDDwNyYaCnwYOvAwtIWr0mYdWgTgAzkIpBcC6YVAIL0QrQQu7fHKsYmXN0gvnA8aDZTRIvBcQyC9EAikFwLphUB6NRvmlW8ahWUbl15Ggj6plagqr926PuHtSr538Rf7wVV87lqTjDZmI43ah175sf4V61fWsK4Lv+Jjk75ndbs1yGjP6zjatQ29TMcqeB+HyZWqjkZ1sGlNVo+5GlYzImump8YFJs+1fT1uryanXD9RNqApCjdN6MpB21YlO6C0pfYJPvCcVnaDociazfS4Ed4ZMyrTd2lNsX39rSx0uTLX38JAhPXJi2XLkpYCQ0YZbTW0/GnVu2NL6t9JMDRJ/z6sLGz6Rh565bneAvzqdOemxwuTQ0lac++mTA+pGbrw+rcz7BnWTmajS5moloOh9PkDiaLw0y3Y9LmfQjF2eaFziTV84bef6Y6f/7PvL8GXjkKM1HF72jTBsz8+DMVIpmf/OPzry9++dH8Hi7cIyT/ogG/EIh1LogskVoTFep3GIhh6/fyhu5i1iBWNLF5+ugDHHnP8/cOnVYNPq7Z89Dokg+zJAp1xGCcfTf6slAV4QQNrr1ujTrAaocYluIXZ5CbgrK+c5X5UC/sQ0++6ctdZY2bPWWOEbD0kgfWQZ89xy06AbtMef4HE3w0aVxFpXKN7+9mLOdcuHAvYu4vcWsT6esG2qYzWwWGqClr9MLT54WWAk2mjTKlKqq7+5KG9yZU0rFBSHJLXOv2F63PJgBS3mhyXymjN311a7r1YIqNNOavLaHmBiDV2QwGS+5i21gNKOZoko60J2s+SyWTXGbFFlaodriBxa+eTlz07UQPBAuCa2LIyroDthZnny8KdCMlx/fsOxmI6dikoo6XvHFfhKHzLtL/9bp9ErN2L09FRvI/RRkt7qlIF9bTYuu8M7JAApO0OKS5K4/T5jdQYraEaVinoyG3UHbBdLS3jatpCSL/rzrGOp62lhGGzmEwmwQMGuwqQxsAQ0x3X7crDjuLafS4Ui93RgLfxX6AQsTTDmCKDsYaPnbQLvQrj5L/xL4kT/mPvVrLnAX6Tix0FiC58mX7mCltAne9jNT64zWTuoDNbUjYbl95HKDT/+OCzZeFm4wezvpBbYj8N8O9XAZyypcwciXKjcotQ5vYqVLdr2XfMuXb35CQnrP0d12z+OJeI9ZItx4npVc8hj9pk7dUGMAdTuxvZnhNLo4y2ytrrrahzNHKZRjb34FeDiy+k11udXk0FPgyNMtpWHFoE4AM5CKQXAumFQCC9EK0ELu3xyrGJlzdIL5wPGg2U0SLwXEMgvRAIpBcC6YVAetUMs0E2iDcHvWhSM3WggsQ1saI61Za/WLE8qIet5r515d6tQ08rXPXlCnUpuWcdTZbJaPFb7NpGr2RyWuMPb5apSFeQlfbMf6NieVAPW819T5N3z8xWSoY3evzSOtos3Rcri2NwjZOjYRW98UpnClZTY/lkE14+VyfKUsGCm+c1MfLnzMNgitSUJtE8rcTWFaOyTLLUPcUUrf2qwrPVKkKwKhStEPTlcYSAFhI28xyLypEx1i/Xxwzli3X9uHKWY1iSaM+0sWDu2sS+vw/kqGXuIkduKiKrcZ7fNsWUu4dD7TmqyEYr7FKSovWDJKGMtta1l+Grank+2e9raTcVyzLL59onpe/h2zzPq8jdCrNp9fsA7zIdmqcVuqZE+Te1c4vcfN/0c30AC0dzc38BLMdrnPkuRPImn15cXx6nW552n3QfmKaZYnfN5WdpHjKYggz32abk1Cfctjw/K/+Cp+nI02xShbS6yy/veopGdXPUdk1R92MiR+67Xsxzqj91nLRr/6D306H2Hp3S+Dth90Qs99KHAOS7kUe10Issvt5+n7c1yRSsz/B8shQ8LWvurPEOvp0VeV45Csb4M16eVpoTluP5iUFhc8royRGnEdDGeWNcHys5TIsKvi+Po04Yp9zpyKBxVAk0KiicMKCb+7xzAsaf99sSfhJc7+kOr32NEt+YUP1y3jO373TLz5Frj4B1Hdv1EdLH/DUXs6H23mGIXLXC7nuOvfMQwGt/izyqguDD0FQmOnApF1CRhvLJigKqGS3NzgqextQcmtP2JgO61aAwlRo4A1/98p6gwdgNS7DANGdh3/I44Cldx/60SH3KRbWleWVFjlv6Wq6oDeSoFf/G9rtpbCslwfV9hJ0Tz3dumuHCXG8lhrd6VpDRXiy90uosE5N6BeEcsw7TmG7t6Hs1ZH3SMxljBr3Fa8Lr6t2L6cgd/DIy7Ou3bnoZasUiaLedjsQqaG0pQsrZTpO7d5Uqak+W5qhluL5DDnTuhFnS3oDbI2EnZd6gOW1N/FmJWtdeelfpbYdhuDpUoGwH/QSfHH8Jw4pX3g87yMxR/B+Wp9X/dLqH0wf49k1wmljfOruzL/QJarbR8V3Oet+XxjntBdZZnKzjrQypD3m5r1RrS6E68KonbeymevAhGJZLylnfy/LjwjJX8grIpwfUkF8GzihBO5rT9uMAZ+5DHtW29pKzr5QYnMorYXXqrOP+BEnhQDDPa4ecI2ul6G1eMtq/YslgX7avFhmDvy5/gFjv2RTMVktsoh+SMvNsI3rb5kDV7M2K+zNvBotj9SqLYmyhPnOkrT45W3bLYzYu3eMJsx+gmtwOJX+upLyk7y6if7I5kHVdu/+SFfL7ifqe2aDdJl0e/Ri5ZsGlfS1rr5qh58uFgqtmkk3U/aNw9XuCufWSlEg29xA6PRdQRltl7bV2esWc5e7oxbJiOb+Kn1T3zxSt2vRKZ4KzEPz9mmZguQ9ltI2jF2JF4MPQKKNtxaFFAD6Qg0B6IZBeCATSC9FK4NIerxybeHmD9MITttEo4OSIwLUXAumFQCC9EEgvBNKr8TCvcBzzCvUH6VUdVHQbSa9ZdGsoD5aVbWnRzoo4RtTtZ5X4W9aUjfZBA2nUhNErmZyWb+Pvyqqqey1EP19WtrdFO8vjmIuvrxJ/75qy0e5ZxNGuKZOjMXfcG6+OsZytTvSgK7qNM/2sqSnH+OnONa+JfW+nG8ROKFJF7leutjWjXBerK8qrKSa3NR+Uo/zT69cU2rYhMwVt6qCs9pPqL7B2bPk9n02Bq65NHFMU22b9EfWJ+IGDtpeNVjbcfvJ4tFzEcbSDhpuNdlb0Ma4eFNmy01qEZ6N1+8Li7ZZPI4+asvbSfW3Ekal5pn291xXdFqeiGWLxz+kPCVslp+qu6Lb7uUNytz8cJCGu9SwSGzn3MP3Yl9Jz97w3zfz35Gf4dwwLL+X2EJNMNG+SFkf35I8ukOp7D830AfRGj7xjPzB1LY12JH3MGGT9EfVQfGpPrxv75je8fupzuYevZuUiTlx5eNG1MyTex+Wpj/Xyjt5/IbLN60vGi/fGB5BHjacXWXz9sa/lupPpUG+fMM6JAp5HVvuwq8LVJmDc0+bcfg1MKMHGChNUskpsbtaYr5bjKl51N2hcHpQdgU9dR/PIGvYLAPJf9+8kDrdLoH0EQLo7dXPWqyN9cXWxop40+Kl9bijH9vqpSfAp/qS1iOOw/Laij2d5HydZXluKe4wZx+vLPi+ejdloq6H+h6GpQiK1P1tRY1umwgVfzVqqwC1R27o2YVEsZcVAgUpXRR5ZoWCl1Sdz4Oj5DrJlbi1Cz8VS95O5sC6W9tHtJ7jK3JD41u9SQGkbykY7UCjsTbrxwjJa/M6x0KhstCPF8mv88Dq3MyS69aLRjU8EbwJwtW3Ihpd7Itae5RfOAssjG/0gU7BqC7yaMEVamP4R2TLsdOSDZe6lSo5PmFCuzBVxdoRz3Yo+uki7vetZvjgJXjxc2VdFF2h1eg6RAxxfdugr/0v/Rf8l+60twQLnkey3JhgJtTulRy53sHJC8EftQyc64MLC5X9MT8JUtkv9ZqxYCNqIf4VTjxj8K/jO+X+6j9ge+O8HIqeWQH35Dy25CNGFLr3TAfXyA3/52JJbF3AX9WKLxCEN/fqbttvPQqHr8EsFWi7iXHfb5SjbpqF5H93WyP9fct57iBV0zmcCfXkEAqNXFm9UF7VGHIxEQnYmSspmC0p4crByyrM8xnlDyZ7yxs+cnCekOd4z+Ciw7K9zi5cj3Cb8wJR1gyy0s8c3Mds7Daagje2Xey5RjaucnaB6VmX0OK+LhvvD6wV4ltnnCl4/T/EctKRcxPkKy2/L7UgfnfCvg0W0d1ulfSHxChIOUw1fe9WMw3csttUum1suN5QPY9dPGbj2qrz2aja9ej7yWNd8m53d9qHPN7K52MXg+gLp1Up6veWAD0OjjLYVhxYB+EAOAumFQHohEEgvRCuBS3u8cmzi5Q3SC+eDRgOz0SLwXEMgvRAIpBcC6YVAerUaZl1Va3Uxg1X4+Gmj0OInJmpOYeAbqtmqRiIP5FpaC7voXjogUh5ZdG3JRqWOirLSKvxd+xIU9Q10MFbQ2NaRyzbkEshVS8qv5e+S4Ty65SitKtg42rXP5Chyx44x3awj8sl+Rx41UjynrD1Kc84C091GucZV5KEF3x5c+e3AAdlmmWu54lWRD6e4ntfLIUvqDgNLLatwhSzNh8vPL5qr1itn7cUV0S6JMBbKdUsxpgntb78mj+o0JzfV8kqLmI22jdZexfRcL8CN2jmba2upMvXg9A9z72XlcNXTyi5mt20+d4Trbne9LvLQevZiGEmC/bNMnObFzbPcssX08c+8b+o4zZlr5RWeea1Pnv4k0B8fyM9lePrbo7k5nhOJ5qr1ypl49pm0aJfyV8Ti/aXYdWGGt5kx8/9Jej8aY1regTzyqH3oxZPGFiYGbfo/jNNB5pShvXOSlYvcscAUEiP8MWPVAI1/hK69B+eslPNzy/K8slT1mpPA5Aq03IRBvwe0Z0Ckv6X5cLkutvBasJzimsBT824s3l+2lDA03ibNm0smbSmXolre1wrIo7ZZ2odTvYbyybrlUomyVahdy+xDzYRzy/ryW6GYnd1eKPJEsyIfLvAsWn55oiSJbknfglHMoSUqo53d5nScGwxn48KlfVss7X3d7Ei4wmG5YyGooO3w1a6ePV+LuRljy3LLBnLImsz292Amxrd7ij0iLSTNVeuXV+hhSd8c95bFVpBp3ty+zLR2K5QqfxFtcN+re0eazHySBjt+Ea7oY7lj+dhymJiccODYmJuHVtifMMybOKvk7Y5CZs8dpbllVeLFf19FOQ3UtjBj5zhnlmZvFvlwaa5avzzlXQByzt5X1rde0PgPYxR/PU7Xh1rK+AG5jDiDj520Hb3mFofIh5jsk+2SC/1OljuWrrB75U+/IjSuis0HHGEfywzSEU7eDFY2dozMcLnS3LKzcel+rqid/YBCbed5FlxpM9XAir2W9wXLlc2us8zelee6nVcHeNeitw3SCSC6XxmdB9gnI4/aY+1V0+qsZTC3XOhbfyuzW6cwG22VtVfb0avZuWNDMPIL628kJgWfUEV6BenVdsuGVrKrMV8uljC0iFNiYIWNh6CxQBltWyztEUgvBALphUB6IXBpj1gvUEaLMlqcD5oJlNEi8FxDIL0QCKQXAumFQHpdMZgt8FifH6Kd6eVElIM9/mPrpVlft6yY5bYS7qriocfq8quSjTZmI402Ar16lPS98JWq1SvniK2EX1X2MK+16vITKK06r+NotxHoVZwwjEsP0RyxcoR/YlRJO8YksLYQt2oOOJpbToeSXtW1T9hMOUuz3o4x9auQwybiqmxQDawS5wPP8EmpLj8YiGhcwzugsVS5hixpKTCU7cijDUCv7qFjDn2cUJ/Lv8i/V9j2k9zMLgBbybh5bKXfgSclt5yia8qzH5iW+oiPmlMYHdJCDgvFqVgGYJeaFreT8z+qzw9yv43xfl2O5uYWABYijrkf4IeYLnQj0Ov1f3h/VEuzHLFCP+vsBk0lfPBzxP7obvis4pZTjBue/XnjLCGnMw4T9PM+6z0Az/PiqhPGJN8u7KzPDyaNizxqdoYpcb9esG3SsZ1Ir2pos2ftzaG9L6yYI9bcklWzAZEsE7l69q7stUxpG8qLS1Wv9fgFstH2F67PJWHshgIk94X1Afisfbv+Qo5igjF/vEKO2JP+2tnoin8tqLB1rRx2P8H8JFe/dlQap728uJ1mfX4w4Fr0wszz5GX34nR0FO9jbJDJMTvkmL0SeeX6WTrOcP2stN1RXZLJ1/R45a6fsL8attO6M7BDZPg7EZy17GG4OsXXeGfq84NFeBuX0RaO2lTBphnG1DJ5wcdONgK9rHtjmwvnySvPEUtXRTcqt8QAfsNyxN43SIv+78TNXrnrJ+y7DhbuJHXvVrLneYUUvL/l58WVf1mfH4xr9jn2Zv7xwWfpMs2W48T0queQRxtj7bUerC7AFXlxzY8+L9XjVwUl2Whx7RVYe9Wfqr3tcGFpxeqe5e4fv/IIffe12VxHPX5V8EdPPxCc4Tve8vRa1gIHA4V5jZ3h8RBgNtoWHFoE4AM5CKQXAumFQCC9EK0ELu3xyrGJlzdILzxhG40CTo4IXHshkF4IBNILgfRCIL3eEsAnUJFeTYBxQGYJa6tpdqtIaRFIrxqQXrwzb+r9K+bApUjioUJ6rR2btRHQtCzX0eqK5Oe1TfQeYBaOKjLSpiKyEgewJUVL4YFDetUCdYL8N5Hnmt1i+hLPa/sC1W10PcUsHp06wvMQvevFfIRMo5+P5V56Ag9cFeDTquGlFZv1eE7QxDMGfaEiRlrwDHugPnHvblcNyc1jcNEOPGqPD2gCFNpT59gGYJkc3atGzprrEonEsrcFu+kpya4te2P0mXJruWewHw8cTo61IDdM/huWQowLSXaplJa/2dIhUxWblHkjsoAHDulVC6btFKTs3wCc9JS0OQdejfgWGTjDpbTL0jidB1XbeP7jeOCq4E0kRGsE7r88c/4p60HCmu6loUkA8q8Q77gws0jfUQw9+cT3rC66tTB6x7fOTILe2fn4/Yf9FrJ4whZRiNY04NIel/aIFgHPtYafu3gIkF5NA6418MoRgfRCIL0QCKQXAumFQHohEEgvBNILgfRCrAnWFfZvrwaQXggcvRBILwSiBPi8V5utvd4MwB8eb8GxrZOe6z3d26ABnBwRuPZCIL0QCFzaI67EdQ4u7Ztx7aizF732ZbLnw17X5Oovp/X6YvvLcb3mHvAqv9fVgiK9Gs4ufpDZ35rZ5X4wutiq3TV0wVpPbN/dglp7YJXsadWguPZqo5sZ9d8SsPSGnRcNjYajV5MHsnrm1TpcrdIbbmuPrdfcA73mHUZ6NWtAsuhfq+YrJ3duJK9rdQXPs87YZe3U1YNKPkivZk54YmWyxjmyDld93bHX24PKPrj2ao+50Vrn1Lb+eVlf/2qu3Afp1UZMrP/r8EZ9kd7oL+TxtmrjqRK8S1Db4Q3cdVqrazjoOhrQ19L5Sve9KvhYSC9EE880nBwRTQTSC4H0QiC9EAikFwLphXhTIPClEGpcEA2CXoFeeAcM0RhYODkicO2FQHohEEgvBNIL8eZC98or/413TYl9b3t6lY5pxQ28RxsqxU9HeHMZJ0cEAumFaHN6WTXWltlZll96hb54sioGtzbE/nh9r9aldj70jRKirfZzBBttrdqG+6NvwEO/9snRssSZ5J0ZFvsjaoJnHLe0Ss4kYeZbt3QYc4MH98Z9sdp6f3gsCPW/3Q/9mkevSr9EYOnhmuC2+6sWnsAy/MMXLeeX7v8t74zf1/bcHxonFLzdD32dk6NuiT8l465eNiaXjc36FR2v9Yqx9fBre+2PVXLkyzvYvoe+gT8CoAd+pGr1w6VbbbESW2Hd2y77U4PCtm0PfXdjjwM9e1b5aQIr8CNlV55feqhPG3Z/2rWr9d730tnvqOj13LkIXBS07OhbZROHtcpdi3bdH2s9N41afui717hjevWR1a/hvAtb6pZXyWtaOjmWRAt2hr4TfWr7/anYz3Y+9IEfAfDP7lLtdnEjfS1c+p3jRup76XeO+mo3s9p0P/QqHwaivT832GBPUSC9NhI23AM6lelV3MAfQWED9335zXY+dL8pThLse5sCH8hBIL0QSC8EAumFQHohkF4IxMoI3pjAX2BCNI9e+PtLCJwcEUgvBALphUB6IZBeCATSC4H0QiAQiNXx/0YeDSkXLoD9AAAAAElFTkSuQmCC</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2012-08-28 13:20:21 +0100" MODIFIED_BY="[Empty name]" NO="2" REF_ID="CMP-001.01" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: Number of children with clinical failure at 2 weeks.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2012-08-29 03:01:30 +0100" MODIFIED_BY="[Empty name]" NO="3" REF_ID="CMP-001.03" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: Change from baseline in night time cough diary score.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2012-08-29 03:01:17 +0100" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.05" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: Change from baseline in night time visual analogue score.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2012-08-28 13:20:21 +0100" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-001.08" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: Lung Function at end point mean change in FVC % from baseline.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2012-09-05 14:08:35 +0100" MODIFIED_BY="[Empty name]" NO="6" REF_ID="CMP-001.09" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: Lung Function at end point mean change in FEV<SUB>1</SUB> % from baseline.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2012-08-28 14:12:35 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2012-05-30 13:55:16 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2012-05-30 13:51:26 +0100" MODIFIED_BY="[Empty name]">CENTRAL search strategy (<I>the Cochrane Library</I>)</TITLE>
<APPENDIX_BODY MODIFIED="2012-05-30 13:55:16 +0100" MODIFIED_BY="[Empty name]">
<P>#1MeSH descriptor Tracheal Diseases explode all trees with qualifiers: DT,SU,TH<BR/>#2MeSH descriptor Trachea explode all trees with qualifiers: AB,SU<BR/>#3MeSH descriptor Bronchi explode all trees with qualifiers: AB,SU<BR/>#4tracheomalac*<BR/>#5tracheo-malac*<BR/>#6trache* near malac*<BR/>#7malacia*<BR/>#8trache* near abnormal*<BR/>#9(#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2012-08-28 14:12:35 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2012-05-30 13:50:45 +0100" MODIFIED_BY="[Empty name]">MEDLINE search strategy (Ovid)</TITLE>
<APPENDIX_BODY MODIFIED="2012-08-28 14:12:35 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Topic search</B>
</P>
<P>1. tracheomalacia$.mp.<BR/>2. tracheo-malac$.mp.<BR/>3. (trache$ adj5 malac$).mp.<BR/>4. malacia$.mp.<BR/>5. exp Tracheal Diseases/dt, su, th [Drug Therapy, Surgery, Therapy]<BR/>6. exp TRACHEA/ab, su [Abnormalities, Surgery]<BR/>7. exp BRONCHI/ab [Abnormalities]<BR/>8. (trache$ adj5 abnormal$).mp.<BR/>9. or/1-8<BR/>10. ADOLESCENT/ or exp CHILD/ or exp INFANT/ or exp PEDIATRICS/<BR/>11. (child$ or paediat$ or pediat$ or adolesc$ or infan$ or toddler$ or bab$ or young$ or preschool$ or pre school$ or pre-school$ or newborn$ or new born$ or new-born$ or neo-nat$ or neonat$).mp.<BR/>12. 10 or 11<BR/>13. 9 and 12</P>
<P>
<B>RCT filter</B>
</P>
<P>1. exp "clinical trial [publication type]"/<BR/>2. (randomised or randomised).ab,ti.<BR/>3. placebo.ab,ti.<BR/>4. dt.fs.<BR/>5. randomly.ab,ti.<BR/>6. trial.ab,ti.<BR/>7. groups.ab,ti.<BR/>8. or/1-7<BR/>9. Animals/<BR/>10. Humans/<BR/>11. 9 not (9 and 10)<BR/>12. 8 not 11</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2012-08-28 14:12:35 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2012-05-30 13:51:01 +0100" MODIFIED_BY="[Empty name]">EMBASE search strategy (Ovid)</TITLE>
<APPENDIX_BODY MODIFIED="2012-08-28 14:12:35 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Topic search</B>
</P>
<P>1. tracheomalac$.mp.<BR/>2. tracheo-malac$.mp.<BR/>3. (trache$ adj5 malac$).mp.<BR/>4. malacia$.mp.<BR/>5. (trache$ adj5 abnormal$).mp.<BR/>6. exp TRACHEOMALACIA/<BR/>7. or/1-6<BR/>8. exp pediatrics/<BR/>9. exp CHILD/ or exp INFANT/ or exp ADOLESCENT/<BR/>10. (child$ or paediat$ or pediat$ or adolesc$ or infan$ or toddler$ or bab$ or young$ or preschool$ or pre school$ or pre-school$ or newborn$ or new born$ or new-born$ or neo-nat$ or neonat$).mp.<BR/>11. 8 or 9 or 10<BR/>12. 7 and 11</P>
<P>
<B>RCT filter</B>
</P>
<P>1. Randomized Controlled Trial/<BR/>2. randomisation/<BR/>3. Controlled Study/<BR/>4. Clinical Trial/<BR/>5. controlled clinical trial/<BR/>6. Double Blind Procedure/<BR/>7. Single Blind Procedure/<BR/>8. Crossover Procedure/<BR/>9. or/1-8<BR/>10. (clinica$ adj3 trial$).mp.<BR/>11. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (mask$ or blind$ or method$)).mp.<BR/>12. exp Placebo/<BR/>13. placebo$.mp.<BR/>14. random$.mp.<BR/>15. ((control$ or prospectiv$) adj3 (trial$ or method$ or stud$)).mp.<BR/>16. (crossover$ or cross-over$).mp.<BR/>17. or/10-16<BR/>18. 9 or 17<BR/>19. exp ANIMAL/<BR/>20. Nonhuman/<BR/>21. Human/<BR/>22. 19 or 20<BR/>23. 22 not 21<BR/>24. 18 not 23</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>